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Summary
Opioids	have	long	held	a	prominent	role	in	the	management	of	perioperative	pain	in	
adults	and	children.	Published	reports	concerning	the	appropriate,	and	inappropriate,	
use	of	these	medications	in	pediatric	patients	have	appeared	in	various	publications	
over	the	last	50	years.	For	this	document,	the	Society	for	Pediatric	Anesthesia	ap-
pointed	a	taskforce	to	evaluate	the	available	literature	and	formulate	recommenda-
tions	with	respect	to	the	most	salient	aspects	of	perioperative	opioid	administration	
in	children.	The	recommendations	are	graded	based	on	the	strength	of	the	available	
evidence,	with	consensus	of	the	experts	applied	for	those	issues	where	evidence	is	
not	available.	The	goal	of	the	recommendations	was	to	address	the	most	important	
issues	 concerning	opioid	administration	 to	 children	after	 surgery,	 including	appro-
priate	assessment	of	pain,	monitoring	of	patients	on	opioid	 therapy,	opioid	dosing	
considerations,	side	effects	of	opioid	treatment,	strategies	for	opioid	delivery,	and	
assessment	of	analgesic	efficacy.	Regular	updates	are	planned	with	a	re‐release	of	
guidelines	every	2	years.
K E Y W O R D S
monitoring,	opioids,	patient‐controlled	analgesia,	recommendations,	side	effects
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1  |  INTRODUC TION
The	 treatment	of	perioperative	pain	 in	 children	has	been	a	 topic	of	
great	interest	to	pediatricians,	pediatric	subspecialists,	surgeons,	and	
anesthesiologists	for	many	years.	It	is	part	of	our	core	mission	to	pro-
vide	high	quality	and	ethical	care	to	pediatric	patients	in	the	perioper-
ative	time	frame.1-6	The	role	of	opioid	medications	in	the	treatment	of	
discomfort	after	surgery	has	been	highlighted	both	as	a	critical	compo-
nent	of	adequate	pain	control	and	as	the	primary	factor	contributing	
to	 perioperative	 complications.7	Unfortunately,	 few	 evidence‐based	
reports	are	available	 to	guide	 the	use	of	opioid	medications	 in	chil-
dren	in	the	perioperative	period.8	The	evidence	that	exists	is	published	
in	a	wide	variety	of	professional	 journals,	newsletters,	meeting	pro-
ceedings,	etc.9	Many	of	the	recommendations	that	have	been	written	
concerning	opioid	administration	address	this	topic	as	a	small	part	of	
overall	pain	management	and	rarely	address	pediatric	specific	issues	
in	detail.10	For	example,	a	recently	published	set	of	recommendations	
regarding	the	management	of	postoperative	pain	covers	many	aspects	
of	perioperative	pain	control,	but	does	not	address	several	important	
issues	 specific	 to	 the	 administration	 of	 opioids	 to	 children,	 such	 as	
nurse‐controlled	analgesia	(NCA),	opioid	contraindications	in	children,	
or	special	monitoring	requirements	in	this	age	group.10
The	 Society	 for	 Pediatric	 Anesthesia	 (SPA)	 initiated	 and	 sup-
ported	 the	 formulation	of	 these	 recommendations	with	 the	 intent	
of	providing	guidance	for	pediatric	anesthesiologists	that	is	(where	
possible)	 evidence‐based	 or	 a	 synthesis	 of	 expert	 opinion	 where	
evidence	is	lacking.	The	authors	did	not	attempt	to	make	this	man-
uscript	all	 encompassing,	but	 rather	were	 interested	 in	addressing	
the	 issues	that	were	felt	 to	be	 in	need	of	clarification	at	this	time.	
This	document	should	not	be	interpreted	as	an	endorsement	of	the	
primacy	of	opioids	in	the	management	of	perioperative	pain.	Rather,	
this	project	begins	with	the	admonition	that	clinicians	should	use	all	
methods	possible	to	minimize	the	use	of	opioids,	 including	the	ad-
ministration	of	adjunctive	systemic	medications,	 regional	anesthe-
sia,	and	alternative	medicine	techniques.
2  | DEFINITIONS
This	document	addresses	topics	related	to	the	use	of	opioid	medica-
tions	including	methods	of	administration,	assessment	of	pain,	opti-
mization	of	therapy,	and	monitoring	of	pediatric	patients	on	opioid	
therapy.	 This	 discussion	will	 largely	 be	 limited	 to	 pharmaceuticals	
available	 in	 North	 America;	 however,	 the	 principles	 of	 care	 apply	
broadly	 to	 any	medications	 in	 the	opioid	 class.	The	 “perioperative	
time	frame”	refers	to	administration	of	opioids	as	part	of	the	anes-
thetic	for	an	operation	and	the	recovery	period.	The	length	of	time	
will	 be	different	based	on	variations	 in	 the	 surgeries	 involved	and	
multiple	patient	factors	including	age	and	pain	sensitization.	For	the	
purposes	of	this	paper,	the	recovery	time	frame	will	be	defined	as	
the	period	 for	which	most	 surgical	patients	would	be	expected	 to	
require	 opiates	 for	 each	 specific	 procedure.	 For	 major	 surgeries,	
this	would	include	time	as	an	inpatient	with	emphasis	on	parenteral	
administration	of	opioids	during	that	 time	period.	We	will	also	ad-
dress	the	brief	time	pediatric	postoperative	patients	receive	oral	opi-
oids	at	home.	We	will	address	the	treatment	of	chronic	pain	patients	
that	come	for	surgery	but	not	the	use	of	opioids	for,	or	the	treatment	
of,	chronic	pain	that	might	develop	after	surgery.
3  | FOCUS
These	recommendations	are	intended	to	address	questions	related	
to	the	use	of	opioid	medications	for	children	undergoing	surgery	or	
painful	procedures.	This	document	is	not	comprehensive	in	nature.	
We	have	chosen	to	highlight	the	areas	of	appropriate	opioid	deliv-
ery	methods,	monitoring,	and	pain	assessment	since	these	aspects	
have	high	variability	between	care	delivery	systems	and	bear	most	
directly	 on	 the	 safe	 use	of	 these	 agents.	 Issues	 involving	 children	
with	chronic	pain	and	pain	sensitization	as	well	as	previous	opioid	
therapy	are	also	addressed	since	these	patients	are	often	the	most	
difficult	to	manage	in	the	perioperative	time	frame.
4  | PURPOSE
These	 recommendations	 are	 intended	 to	 enable	maximum	patient	
benefit	from	opioid	medications	in	order	to	provide	potent	analgesia	
and	best	outcomes	for	children	after	surgery.11,12	We	also	intend	to	
provide	appropriate	caution	concerning	the	potential	serious	side	ef-
fects	associated	with	their	administration.7	The	collective	purpose	is	
to	promote	appropriate	and	safe	practice,	while	also	dispelling	un-
reasonable	fear	of	their	administration.
5  | TA SK FORCE MEMBERS AND 
CONSULTANTS
The	SPA	board	approved	the	appointment	of	nine	primary	authors	to	
review	the	published	evidence	and	make	recommendations	on	issues	
related	to	the	safe	use	of	opioids	in	children.	Those	appointed	come	
from	a	diverse	array	of	 institutions	and	sub‐specialty	backgrounds	
including	pain	medicine,	clinical	pharmacology,	clinical	trials,	addic-
tion	medicine,	general	operating	room	anesthesia,	and	perioperative	
nursing.	We	also	engaged	four	senior	anesthesiologists	with	exten-
sive	histories	of	contribution	to	the	specialty	of	pediatric	anesthesi-
ology,	pain	management,	and	opioid	investigation.
6  | TOPIC S AND STRENGTH OF E VIDENCE
The	 expert	 panel	was	 convened	 and	met	 in	 person	 twice	 prior	 to	
beginning	 the	process	of	 formulating	 these	 recommendations.	 The	
members	agreed	that	this	manuscript	should	focus	on	the	periopera‐
tive	time	frame	and	specifically	on	the	process	of	opioid	delivery	and	
monitoring	of	patients	 treated	with	opioids.	The	panel	 also	 agreed	
     |  549CRAVERO Et Al.
the	document	should	attempt	to	target	those	issues	most	pressing	for	
health	care	providers	who	manage	pediatric	patients	in	the	perioper-
ative	time	frame.	Selected	topics	were	to	include	age‐related	effects	
of	opioids;	patient‐controlled	analgesia	(PCA);	postoperative	outpa-
tient	opioid	 administration;	monitoring	of	patients	on	opioids;	 pain	
assessment	 and	opioid	efficacy;	opioid	 side	effects	 and	 treatment;	
perioperative	management	of	patients	on	chronic	opioids;	and	man-
agement	of	patients	with	opioid	addiction.	Several	sections	that	were	
initially	written	for	this	manuscript	were	eliminated	due	to	editorial	
considerations	of	overlapping	content	with	other	published	reports.
The	 members	 of	 the	 taskforce	 searched	 academic	 databases	
for	relevant	articles	on	opioid	administration	in	children	associated	
with	surgical	pain	relief	 including	effectiveness,	 techniques	for	de-
livery,	monitoring,	and	side	effects.	A	list	of	the	databases	searched	
and	 the	 search	 terms	used	 is	 presented	 in	 Table	A1.	Age	 limits	 of	
0‐18	 years	were	 set	 however,	 adult	 data	were	 included	when	 the	
collected	 opinion	 of	 the	 taskforce	 determined	 that	 pediatric	 ev-
idence	 base	was	 lacking,	 but	 adult	 studies	 offered	 robust,	 reliable	
data.	Recommendations	were	downgraded	when	evidence	was	from	
adult	cohorts.	All	papers	present	 in	the	databases	were	eligible	for	
inclusion	with	no	“beginning”	date	and	ending	January	of	2016.	Each	
study	was	classified	as	retrospective,	prospective	observational,	pro-
spective	randomized,	or	prospective,	randomized	and	blinded.	One	
author	was	responsible	for	the	literature	search	for	each	section	and	
reviewed	the	papers	that	were	generated.	This	individual	then	deter-
mined	which	papers	provided	evidence	that	was	appropriate	for	the	
section.	Many	older	papers	were	 judged	 to	 involve	medications	or	
modalities	that	were	not	relevant	to	the	current	standard	of	care.	The	
written	text	for	each	section	(along	with	the	references	to	support	
the	text)	were	evaluated	by	all	members	of	the	taskforce	including	
consultants.	The	group	specifically	reviewed	the	type	of	studies	that	
were	available	to	support	the	recommendations	in	each	section	and	
considered	the	level	of	evidence	as	proposed	by	the	author.	The	task-
force	met	in	person	four	times	and	there	were	six	conference	calls	
arranged	to	facilitate	these	discussions.	Where	there	was	a	question	
as	to	whether	a	study	should	be	included,	it	was	discussed	and	nego-
tiated	until	all	members	felt	comfortable	with	the	decision	to	include	
or	reject.	Similarly,	text	for	each	section	including	the	recommenda-
tions	were	adjusted	until	there	was	unanimous	agreement	among	the	
members	of	the	committee	and	the	consultants.	Recommendations	
that	could	not	be	unanimously	agreed	upon	were	not	included.	After	
the	document	was	completed,	the	entire	manuscript	was	reviewed	
by	 the	Board	of	Directors	of	SPA.	Board	members	offered	editing	
recommendations	and	feedback,	but	did	not	fundamentally	change	
the	level	of	evidence	or	the	nature	of	the	recommendations.
The	strength	of	evidence	available	for	specific	recommendations	
was	based	on	a	three‐tiered	classification	system	that	we	patterned	
after	evidence‐based	practice	guidelines	from	the	American	Society	
or	Anesthesiologists13:
•	 Level	A:	Based	on	prospective,	randomized	trials,	or	pharmacoki-
netic	and	pharmacodynamic	trials	that	meet	the	highest	standards	
for	investigation	and	reporting.
•	 Level	 B:	 Based	 on	 prospective,	 observational	 data	 or	 appropri-
ately	 conducted	 retrospective	 analysis	 with	 consideration	 of	
appropriate	confounders	and	compensation	for	the	 influence	of	
these	factors.
•	 Level	C:	Based	on	case	reports,	case	series,	or	consensus	involv-
ing	experts	who	presented	a	well‐defined	process	for	formulating	
conclusions.
For	each	recommendation,	we	have	taken	the	level	at	which	the	
preponderance	of	evidence	was	derived	and	clearly	designated	it	as	
such.	A	list	of	the	recommendations	and	strength	of	evidence	is	pro-
vided	in	Table	1.
7  | AGE‐REL ATED PHARMACOKINETIC 
AND PHARMACODYNAMIC OPIOID 
EFFEC TS
To	be	discussed	in	this	section:
•	 What	is	the	evidence	for	changes	in	opioid	pharmacokinetics	and	
pharmacodynamics	with	age?
•	 How	should	opioid	dosing	be	adjusted	with	age?
•	 Specifically,	what	 is	 the	effect	of	 age	on	 the	 issue	of	opioid	 in-
duced	respiratory	depression?
Recommendations	for	dosing	opioids	in	children	are	cited	in	a	number	
of	publications.6,14,15	The	appropriate	dose	for	a	given	patient	will	vary	
with	many	factors,	including	the	invasiveness	of	the	surgery,	adjunctive	
medications,	previous	exposure	to	opioids,	and	underlying	illnesses.7,16 
The	pharmacokinetics	 and	pharmacodynamics	 of	 opioid	 agents	 also	
varies	with	age.	Multiple	investigators	have	evaluated	age‐related	opi-
oid	 pharmacokinetics	 and	 pharmacodynamics	 primarily	 using	 obser-
vational	methodologies.17,18	It	is	important	to	note	that	among	these	
studies	 there	 is	 a	 poor	 correlation	 between	measured	 blood	 opioid	
concentrations	 and	 patient	 analgesia.	Many	 factors	 confound	 these	
studies	 and	 contribute	 to	 the	 lack	 of	 correlation.	 Most	 prominent	
among	these	is	that	pain	perception	is	subjective	(anxiety	and	consti-
tutional	pain	sensitivity	play	a	role)	and	the	tools	used	to	study	pain	in	
children	vary	widely.	In	spite	of	this,	there	are	some	consistent	findings	
with	respect	to	opioid	pharmacokinetics	and	pharmacodynamics	that	
are	 important	to	consider	when	providing	perioperative	pain	control	
with	these	medications.
7.1 | Pharmacokinetics/pharmacodynamics of 
morphine in children
Morphine	 is	 a	 commonly	 employed	 agent	 for	 pain	 control	 in	 new-
borns,	 infants,	 and	 children.	 There	 is	 consistent	 evidence	 that	 the	
greatest	variation	 in	pharmacokinetic	parameters	occurs	 in	neonates	
and	very	young	infants.	Neonates	have	a	larger	volume	of	distribution	
and	decreased	protein	binding	which	results	in	a	greater	free	fraction	
of	 the	 opioid.	 Glomerular	 filtration	 rate	 (GFR)	 and	 hepatic	 enzyme	
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TA B L E  1  Society	for	Pediatric	Anesthesia	Opioid	recommendations	for	the	use	of	opioids	in	children	during	the	perioperative	period	
with	strength	of	evidence	noted
Recommendation
Level of 
evidence
Age	related	pharmacokinetic	and	pharmacodynamic	opioid	effects
A	validated,	age‐adjusted	morphine	dosing	regimen	should	be	used	for	all	pediatric	patients	but	particularly	for	neonates	where	
the	dose	and	dosing	interval	will	need	to	be	altered	significantly.
A
Dosage	of	most	synthetic	opioids	should	be	decreased	in	neonates	during	the	first	two	to	four	weeks	of	life	(and	for	premature	
neonates	until	at	least	44	weeks	post	conceptual	age).	For	remifentanil,	the	effective	half‐life	in	neonates	is	similar	to	that	of	
older	children	and	adults,	and	thus	requires	no	adjustment.	There	is	sparse	information	on	methadone,	but	it	appears	to	have	
similar	pharmacokinetics	across	all	age	ranges.
B
Dosage	of	most	synthetic	opioids	should	be	decreased	in	neonates	during	the	first	two	to	four	weeks	of	life	(and	for	premature	
neonates	until	at	least	44	weeks	post	conceptual	age).	For	remifentanil,	the	effective	half‐life	in	neonates	is	similar	to	that	of	
older	children	and	adults,	and	thus	requires	no	adjustment.	There	is	sparse	information	on	methadone,	but	it	appears	to	have	
similar	pharmacokinetics	across	all	age	ranges.
B
The	use	of	patient	controlled	analgesia	(PCA)
The	use	of	PCA	opioid	delivery	is	preferable	to	IM	opioid	delivery	for	perioperative	pain	control.	IM	administration	of	opioids	is	
not	recommended	as	a	primary	pain	control	modality.
B
PCA	opioid	delivery	is	safe,	efficacious,	and	correlated	with	higher	patient	satisfaction	when	compared	to	intermittent	intrave-
nous	opioid	analgesia.
B
There	is	insufficient	and	conflicting	evidence	to	recommend	the	use	of	a	specific	opioid	over	another	for	PCA	post‐operative	pain	
control.	Due	to	the	risk	of	accumulation	of	toxic	metabolites	(normeperidine)	that	may	cause	seizures,	meperidine	is	not	recom-
mended	by	our	expert	panel.
B
There	is	conflicting	and	insufficient	evidence	to	indicate	a	difference	in	overall	analgesia,	sleep	patterns,	or	adverse	events	with	
the	addition	of	continuous	opioid	infusion	to	PCA	in	children.	Use	of	a	basal	infusion	should	be	individualized	based	on	consid-
eration	of	the	clinical	situation,	pain	severity,	and	risk	factors.
B
There	is	evidence	that	nurse	controlled	analgesia	and	parent	controlled	analgesia	is	associated	with	safety	and	efficacy	outcomes	
that	are	similar	to	that	of	standard	PCA	therapy.	These	methods	must	be	applied	in	an	institutionally‐sanctioned	program	with	
appropriate	training	and	monitoring.
B
The	use	of	ketorolac	should	be	strongly	considered	as	an	adjunct	to	PCA	for	pediatric	perioperative	pain	control.	Most	evidence	
available	for	NSAID	effect	on	PCA	dosing	involves	ketorolac,	however	there	is	good	reason	to	assume	another	NSAID	would	
have	a	similar	PCA	dose	sparing	effect.
A
The	use	of	acetaminophen	should	be	considered	as	an	adjunct	to	PCA	for	pediatric	perioperative	pain	control. A
Recommendations	for	outpatient	post‐operative	opioid	use	in	children
Educational	resources	must	be	provided	to	inform	parents	of	the	appropriate	indications	for	pain	medications	and	strategies	for	
the	safe	use	of	opioids,	non‐opioids	and	other	measures	to	manage	their	child’s	post‐operative	pain.	Parents	should	receive	both	
verbal	and	written	detailed	discharge	instructions	regarding	home	pain	management	with	instructions	regarding	safe	storage	and	
disposal	of	leftover	medications.
C
Here	is	evidence	to	advise	against	the	use	of	tramadol	for	specific	populations	of	pediatric	patients,	particularly	young	patients	
(under	12)	and	those	with	OSA.
B
There	is	insufficient	evidence	to	recommend	PRN	vs.	scheduled	dosing	strategies	for	opioids	after	surgery	in	children.	Expert	
consensus	is	to	use	a	PRN	strategy	until	further	evidence	is	available.
C
Opioid	pain	medications	should	not	be	prescribed	with	benzodiazepines	except	in	children	for	whom	there	is	a	specific	indication	
and	alternative	treatment	options	are	inadequate.	Doses	should	be	limited	to	the	lowest	effective	level	and	parents	should	be	
warned	about	the	potential	for	excessive	sedation	and	respiratory	depression.
C
Opioid	prescriptions	should	be	limited	to	that	required	for	the	expected	period	of	severe	pain	after	surgery	(local	laws	may	set	
limits	for	quantity	or	time	parameters	for	opioid	prescriptions).	Patients	should	be	educated	concerning	the	appropriate	storage	
and	disposal	of	opioids.
B
Opioid	treatment	of	the	patient	with	chronic	pain	scheduled	for	major	surgery
For	pediatric	patients	with	chronic	pain	who	are	maintained	on	opioids,	continue	established	preoperative	dosing	during	the	
perioperative	period	as	a	baseline.	Acute	post‐surgical	analgesia	should	be	provided	over	and	above	the	baseline	opioids.	Use	
of	non‐opioid	analgesia	is	encouraged	including	regional	analgesia	techniques,	alpha‐2	agonists,	ketamine,	acetaminophen,	non-
steroidal	anti‐inflammatory	drugs,	and	neuropathic	pain	medications	such	as	gabapentinoids	or	antidepressants.
C
If	a	patient	with	chronic	pain	on	opioid	therapy	undergoes	surgery	and	the	patient’s	underlying	pain	source	was	independent	of	
the	surgery,	the	patient’s	baseline	pain	should	continue	to	be	managed	by	the	physician	who	had	been	doing	so	preoperatively.	
Opioid	analgesics	for	the	perioperative	pain,	if	needed,	should	be	prescribed	in	limited	quantities	consistent	with	the	degree	of	
physiologic	trespass.
C
(Continues)
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development	are	relatively	immature	in	neonates	(0‐28	days	of	life)	re-
sulting	in	a	decreased	clearance	of	morphine	at	approximately	one‐fifth	
to	less	than	one‐tenth	of	that	in	older	children	and	adults.19,20	There	is	
considerable	evidence	from	multiple	observational	trials	that	indicating	
morphine	clearance	 is	 increased	via	glucuronidation	 in	older	children	
when	 compared	 to	 neonates.14	 Notably	 neonates	 have	 consistently	
Recommendation
Level of 
evidence
For	pain	management	of	patients	with	central	sensitization	–	strategies	should	be	similar	to	those	for	pediatric	pain	patients	on	
chronic	opioids	(use	non‐opioid	analgesic	techniques	to	the	greatest	extent	possible).	Opioids	should	be	prescribed	as	needed.	
These	patients	benefit	from	the	involvement	of	a	pain	physician	for	the	purposes	of	assuring	appropriate	use	and	discontinuation	
of	medications	in	a	reasonable	time	frame.
C
Assessment	of	pain	and	analgesic	efficacy
Regular	pain	assessments	should	be	part	of	the	perioperative	care/treatment	of	pediatric	patients	who	are	receiving	opioid	
medications.	These	assessments	should	be	made	using	validated	measures.	The	pain	assessment	should	consider	the	unique	
circumstances	of	the	child’s	psychological	state	and	the	extent	of	surgery.
B
Pain	intensity	scores	can	be	used	to	assess	a	child’s	perceived	degree	of	discomfort.	However,	decisions	to	administer	analgesics	
should	take	into	consideration	patient	functional	behaviors,	situational	factors	such	as	pain	source,	self‐reported	pain	scores,	
parental	observation,	and	other	potential	sources	of	distress,	rather	than	arbitrarily	selected	pain	score	cutoffs.
B
Behavioral	observation	can	be	used	to	assess	pain‐related	distress	in	children.	Directions	to	administer	analgesics	in	children	who	
cannot	self‐report	should	take	into	consideration	situational	factors	such	as	pain	source,	observational	pain	scores,	and	other	
potential	sources	of	distress,	rather	than	arbitrarily	selected	pain	score	cut‐offs.
B
Changes	in	pain	scores	should	be	used	in	conjunction	with	other	verbal/behavioral	measures	as	indicators	of	pain	relief	and	anal-
gesic	response	(e.g.	side	effects)	when	making	analgesic	decisions.
B
Physiologic	parameters	should	be	used	to	assess	the	child’s	nociceptive	response	when	it	is	not	possible	to	assess	pain	with	self‐
report	of	behavioral	measures	(e.g.,	when	the	child	is	sedated	or	is	receiving	neuromuscular	blockers).	It	is	recommended	that	
other	potential	sources	of	physiologic	distress	(e.g.,	emotional	distress,	hypovolemia,	fever,	hypercarbia)	be	considered	and/or	
ruled	out	when	making	treatment	decisions.
B
A	child’s	functional	recovery	should	be	assessed	to	inform	treatment	plans. C
Assessing	pain	location	is	recommended	to	differentiate	incisional	pain	from	other	potential	sources	of	postoperative	pain.	The	
nature	of	pain	should	be	assessed	to	assist	in	the	differentiation	of	pain	type.
B
Monitoring	of	patients	on	perioperative	opioid	therapy
Physiologic	monitoring	of	children	receiving	initial	intravenous	opioid	treatment	should	include	pulse	oximetry	for	the	first	24	
hours.	Continuous	monitoring	of	respiratory	rate	and	ECG	should	be	considered	in	pediatric	patients	who	are	on	oxygen,	or	who	
have	risk	factors	for	respiratory	depression.	Physiological	monitoring	may	be	suspended	when	the	patient	is	alert,	awake,	and/or	
ambulating.
C
Although	not	specifically	addressed	in	the	literature,	the	expert	panel	recommends	frequent	assessment	of	the	quality,	as	well	as	
the	rate	of	respirations,	should	be	performed	by	direct	observation	and	recorded	in	the	medical	record.	Increased	frequency	and	
intensity	of	these	observations	is	recommended	for	children	in	high‐risk	groups	in	addition	to	standard	electronic	monitoring.
C
Patients	with	obstructive	sleep	apnea,	obesity	(>95	percentile	BMI),	and	recurrent	nighttime	oxygen	desaturations	are	at	higher	
risk	for	opioid	induced	respiratory	depression.	Opioid	dosing	should	be	based	on	ideal	or	lean	body	weight	and	the	dose	of	opioid	
should	be	reduced	by	50%	to	67%.	Additionally,	extended	respiratory	monitoring	is	required	when	opioids	are	being	adminis-
tered	to	this	population	in	the	perioperative	period.
B
Patients	receiving	opioid	analgesia	perioperatively	should	have	regular	assessment	of	their	level	of	sedation	using	a	validated	
sedation	score	that	evaluates	level	of	alertness	or	mentation,	rather	than	utilizing	a	procedural	sedation	scale.	This	rating	should	
be	part	of	the	medical	record	along	with	measures	of	pain	and	physiological	status.
C
Review	of	code	team	calls	or	emergency	response	calls	and	delivery	of	emergent	naloxone	doses	should	be	part	of	institutional	
efforts	to	critically	evaluate	and	reduce	preventable	opioid‐related	adverse	events.
B
Opioid	side	effects	in	children
Naloxone	infusion	is	helpful	in	treating	and	possibly	preventing	opioid‐induced	pruritus. A
Expert	consensus	supports	the	use	of	nalbuphine	although	there	is	conflicting	evidence	concerning	its	effectiveness	at	this	time. C
Opioid	use	should	be	minimized	where	possible	to	decrease	the	incidence	of	nausea	and	vomiting. A
Naloxone	infusion	should	be	considered	for	intravenous	opioid	therapy	for	the	prevention	or	treatment	of	nausea	and	vomiting. A
It	is	reasonable	to	consider	common	anti‐emetic	medications	for	the	treatment	or	prevention	of	nausea	and	vomiting	while	on	
intravenous	opioid	therapy.	Preference	should	be	for	non‐sedating	medications.
A
Postoperative	opioid‐induced	ileus	may	be	improved	with	methylnaltrexone	in	infants	and	children. B
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been	shown	to	have	at	least	a	50%	lower	glucuronidation	rate,	which	
contributes	to	a	lower	clearance.	In	one	study,	following	a	single	intra-
venous	dose	of	morphine	(0.1	mg/kg)	to	20	neonates	with	a	gestational	
age	of	26‐40	weeks,	the	free	fraction	of	drug	was	80%	compared	to	
65%	in	adults.	This	finding,	combined	with	lower	morphine	clearance,	
mandates	longer	dosing	intervals	in	this	age	group.21,22	In	addition,	the	
primary	metabolite	of	morphine	(morphine‐6‐glucoronide	[M‐G‐6])	has	
a	greater	analgesic	and	respiratory	depressant	effect	than	morphine.	
These	effects	are	amplified	in	the	setting	of	decreased	renal	clearance	
typical	of	neonates.23	Finally,	opioid	dosing	should	take	into	considera-
tion	that	the	blood	brain	barrier	is	more	permeable	in	neonates,	leading	
to	the	potential	for	less	fat	soluble	opioids	to	cause	increased	risk	of	
respiratory	depression.	Using	a	nonlinear	dosing	regimen,	a	relatively	
predictable	serum	level	of	morphine	can	be	achieved	in	pediatric	pa-
tients	in	spite	of	a	broad	range	of	clearance	rates.24	An	evidence‐based	
model	has	been	validated	using	multiple	large	datasets	involving	pedi-
atric	patients	who	received	morphine	for	pain	control.25	A	dosing	regi-
men	based	on	 this	model	has	been	prospectively	validated.26	 In	 this	
regimen,	doses	 for	neonates	under	10	days	of	 life	 receive	50%‐70%	
lower	doses	compared	to	older	patients.	Efficacy	has	been	shown	to	
be	maintained	with	this	regimen	while	risk	of	overdosing	is	decreased.	
Neonates	with	increased	abdominal	pressure	or	use	of	vasoactive	med-
ications	may	further	delay	clearance	due	to	changes	in	hepatic	blood	
flow.17	 Maturation	 of	 clearance	 and	 underlying	 metabolic	 pathways	
occurs	relatively	rapidly	during	infancy	and	reaches	the	levels	of	older	
children	by	approximately	6	months	of	age.17,19,23	Children	2‐11	years	of	
age	actually	have	a	higher	clearance	rate	and	larger	volume	of	distribu-
tion	than	older	children	or	adults.27
Recommendation:	 A	 validated,	 age‐adjusted	 morphine	 dosing	
regimen	should	be	used	for	all	pediatric	patients	but	particularly	for	
neonates	where	the	dose	and	dosing	interval	will	need	to	be	altered	
significantly.
Strength of evidence:	A.
7.2 | Pharmacokinetics/pharmacodynamics of 
opioids other than morphine
There	 is	 considerably	 less	 evidence	 concerning	 pharmacokinetics	
and	pharmacodynamics	of	opioids	other	than	morphine.	Data	on	fen-
tanyl,	sufentanil,	and	alfentanil	indicate	each	of	these	drugs	undergo	
much	more	rapid	clearance	in	infants	and	older	children	relative	to	
neonates.28,29	 Additionally,	 there	 is	 evidence	 that	 premature	 and	
term	neonates	have	considerably	lower	clearance	of	alfentanil	when	
compared	to	infants	and	children.30	On	the	other	hand,	remifentanil	
clearance	is	greatest	in	neonates	and	decreases	with	age	while	vol-
ume	of	distribution	has	an	opposite	trend	yielding	half‐lives	that	ap-
pear	similar	across	all	age	groups.31	There	are	no	data	on	the	safety	
or	effectiveness	of	synthetic	opioids	in	pediatric	patients,	other	than	
fentanyl,	when	used	outside	of	the	perioperative	time	frame.	Their	
use	can	not	be	recommended	in	other	clinical	situations.
The	pharmacokinetics	 of	methadone	has	 been	 studied	 in	 ado-
lescents	undergoing	major	spinal	surgery	and	appears	to	be	similar	
to	that	in	adults	including	an	elimination	half‐life	of	44.4	hours.32,33 
There	are	sparse	data	on	the	pharmacokinetics	or	pharmacodynam-
ics	of	methadone	vs	other	(shorter	acting)	opioids	for	perioperative	
pain	 control	 in	 children.	 A	 small	 study	 of	 postoperative	 patients	
demonstrated	a	propensity	for	more	prolonged	respiratory	depres-
sion	after	methadone	when	compared	to	pethidine	or	morphine.34 
One	prospective,	randomized,	blinded	study	comparing	methadone	
to	 morphine	 administered	 in	 the	 PACU	 found	 that	 patients	 who	
received	methadone	perioperatively	had	lower	pain	scores	and	re-
quired	 fewer	 supplemental	medications	 in	 the	 36	 hours	 following	
their	PACU	stay.35	In	this	study	of	35	patients,	there	were	no	major	
adverse	 events.	 Another	 investigation	 evaluated	 the	 accumulated	
information	on	methadone	pharmacokinetics	in	infants	and	children	
found	no	evidence	of	maturation	of	clearance	with	age.36
Recommendation:	 Dosage	 of	 most	 synthetic	 opioids	 should	 be	
decreased	 in	 neonates	 during	 the	 first	 2‐4	 weeks	 of	 life	 (and	 for	
premature	 neonates	 until	 at	 least	 44	weeks	 post	 conceptual	 age).	
For	 remifentanil,	 the	 effective	 half‐life	 in	 neonates	 is	 similar	 to	
that	of	older	children	and	adults,	and	thus	requires	no	adjustment.	
Methadone	pharmacodynamics	effects	are	prolonged	compared	to	
morphine	and	the	pharmacokinetic	profile	appears	to	be	consistent	
across	pediatric	age	ranges.
Strength of evidence:	B.
7.3 | Respiratory depression
Evidence	concerning	 the	 respiratory	depressant	effects	of	opioids	
in	children	vs	adults	is	sparse.	In	one	study,	Lynn	et	al	evaluated	the	
respiratory	 depressant	 effects	 in	 30	 newborns‐toddlers	 receiving	
morphine	infusions	after	cardiac	surgery.	No	age‐related	differences	
in	 respiratory	 effects	were	 observed	 at	 similar	morphine	 concen-
trations.37	 Similarly,	 in	 a	 small	 study	of	pediatric	patients	 (11	days	
to	7	years	of	age)	 receiving	morphine	after	major	surgery,	Olkkola	
et	 al	 found	 no	 difference	 in	 the	 respiratory	 depressant	 effects	 of	
morphine	between	 the	 youngest	 and	oldest	 patients.19	 In	 a	 study	
of	fentanyl‐related	respiratory	depression,	Hertzka	et	al	found	the	
elevation	of	PaCO2	correlated	with	increasing	plasma	fentanyl	con-
centrations,	but	did	not	differ	between	groups	of	infants	vs	children	
(1‐5	years	of	age)	vs	adults.38	The	authors	concluded	there	is	no	evi-
dence	of	increased	sensitivity	to	respiratory	depression	in	children	
over	3	months	of	age	when	compared	to	adults.	On	the	other	hand,	
a	 case	 review	of	pediatric	 patients	with	opioid‐related	 respiratory	
depression	 found	 that	 age	 less	 than	1	year	 is	 an	 independent	 risk	
factor.	Other	similar	reports	lacked	serum	drug	level	data.39
Recommendation:	Term	infants	(older	than	3	months	of	age)	are	
not	at	increased	risk	of	respiratory	depression	due	to	opioids	when	
compared	to	older	children	and	adults	at the same blood concentra‐
tion of opioid.	The	dose	of	opioids	(dose/kg)	should	be	similar	to	older	
infants	and	children	after	6	months	of	age	 (considering	underlying	
health	 and	 previous	 exposure	 to	 opioids).	When	 beginning	 opioid	
dosing	in	infants	younger	than	3	months	of	age,	the	patient	should	
be	 in	 a	 highly	monitored	 environment	 (such	 as	 a	 step‐down	 unit,	
PACU,	or	ICU/NICU).
Strength of evidence:	B.
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8  | THE USE OF PC A
Issues	to	be	discussed	in	this	section:
•	 How	does	PCA	opioid	delivery	compare	to	other	modes	of	opioid	
delivery?
•	 What	is	the	best	opioid	to	use	for	PCA	therapy?
•	 What	is	the	evidence	surrounding	the	use	of	NCA	or	parent‐con-
trolled	analgesia?
•	 What	 kinds	of	 adjunctive	medications	 should	be	 added	 to	PCA	
opioid	therapy?
8.1 | Introduction—PCA vs intramuscular 
opioid delivery
Patient‐controlled	 analgesia	 delivery	 of	 opioids	 has	 become	 the	
standard	for	analgesia	after	major	surgery	in	children.	This	section	
will	compare	this	delivery	method	vs	other	opioid	delivery	modali-
ties.	There	are	many	adult	studies	comparing	PCA	to	intramuscular	
(IM)	opioids.	One	meta‐analysis	examined	15	randomized	controlled	
trials	 including	787	adult	patients	found	PCA	provided	greater	pa-
tient	 satisfaction	 and	 improved	 pain	 relief,	 as	 reported	 by	 visual	
analog	scale	(VAS)	scores,	and	no	difference	in	side	effects.36	Three	
pediatric	studies	were	 identified	but	were	not	randomized	or	con-
trolled.40-42	These	 studies	 found	 improved	pain	control	with	PCA,	
as	measured	by	VAS,	despite	similar	consumption	of	opioid	equiva-
lents.	None	of	these	studies	found	a	higher	level	of	adverse	events	
for	PCA	use	as	compared	to	IM	opioids.	One	study	found	a	higher	
level	of	sedation	in	the	IM	morphine	group	compared	to	PCA.40
Recommendation:	The	use	of	PCA	opioid	delivery	is	preferable	to	
IM	opioid	delivery	for	perioperative	pain	control.	IM	administration	
of	opioids	is	not	recommended	as	a	primary	pain	control	modality.
Strength	of	Evidence:	B.
8.2 | PCA vs intermittent IV opioids
There	were	no	randomized	controlled	studies	 identified	 that	com-
pared	PCA	with	 intermittent	opioid	administration	 in	the	pediatric	
population.	A	number	of	cohort	studies	supported	the	use	of	PCA	
as	efficacious	and	with	acceptable	rates	of	adverse	events	in	a	va-
riety	 of	 postoperative	 settings	 (abdominal,	 laparoscopic,	 thoracic,	
orthopedic	 surgery)	 and	with	 a	 variety	 of	 opioid	 choices	 (meperi-
dine,	 fentanyl,	morphine).43-56	Higher	quality	data	exist	 for	 adults.	
Meta‐analysis	 of	 randomized	 controlled	 trials	 in	 the	 adult	 perio-
perative	 population,	 performed	 for	 the	 purpose	 of	 updating	 the	
American	Society	of	Anesthesiologist's	 (ASA)	guidelines,	 found	no	
analgesic	 benefit	 of	 PCA	 over	 nurse‐administered	 IV	 opioids.57	 A	
Cochrane	review	of	49	studies	and	3412	patients	comparing	PCA	to	
intermittent	dosing	for	postoperative	pain	showed	that	patients	who	
received	PCA	reported	 lower	pain	scores	 (nine	 to	10	points	 lower	
on	a	100‐point	VAS),	greater	satisfaction,	but	used	more	morphine	
equivalents	(7	mg	more	in	the	first	24	hours).	There	was	no	differ-
ence	in	adverse	events	except	for	a	higher	incidence	of	pruritus	(15%	
vs	8%).58-60	Finally,	Faerber	et	al	used	propensity	matched	cohorts	
to	evaluate	major	adverse	events	and	 found	that	PCA	was	associ-
ated	with	a	lower	risk	of	cardiopulmonary	resuscitation	(CPR)	or	the	
need	for	mechanical	ventilation	when	compared	to	intermittent	IV	
dosing.59
Recommendation:	 PCA	 opioid	 delivery	 is	 safe,	 efficacious,	 and	
correlated	with	higher	patient	satisfaction	when	compared	to	inter-
mittent	intravenous	opioid	analgesia.
Strength of evidence:	B	(largely	based	on	adult	data).
8.3 | Opioid selection for PCA in children
The	 evidence	 is	 sparse	 and	 inconclusive	 concerning	 the	 choice	 of	
opioid	 for	 PCA	 in	 children.	 One	 randomized	 controlled	 trial	 of	
morphine	 vs	meperidine	 in	 50	 orthopedic	 patients	 8‐16	 years	 old	
showed	 no	 difference	 in	 side	 effects,	 but	 lower	 numerical	 rating	
scale	 pain	 scores	 in	 patients	 receiving	morphine.60	 Another	 rand-
omized	controlled	study	of	60	children	posttonsillectomy	compared	
tramadol	to	morphine,	with	poorer	pain	control,	similar	sedation	lev-
els,	and	lower	nausea	scores	in	the	tramadol	cohort.61	Comparison	
of	morphine	and	hydromorphone	in	a	randomized	controlled	trial	of	
96	 pediatric	 patients	 showed	 no	 difference	 in	 pain	 control,	 as	 re-
ported	by	VAS,	with	morphine	equivalents	administered	(assuming	
1:5	potency	ratio),	or	side	effects	(hypoxia,	pruritus,	nausea,	urinary	
retention).62	A	retrospective	comparison	study	of	morphine	and	hy-
dromorphone	including	514	pediatric	patients	at	a	single	center	re-
vealed	more	frequent	conversion	from	morphine	to	hydromorphone	
due	to	pruritus	and	poor	pain	control.63	The	nature	of	this	study	did	
not	allow	for	a	determination	of	overall	superiority	of	one	drug	vs	
another	in	terms	of	pain	control	or	side	effects.
Recommendation:	There	 is	 insufficient	 and	conflicting	evidence	
to	 recommend	 the	 use	 of	 a	 specific	 opioid	 over	 another	 for	 PCA	
postoperative	pain	control.	Due	to	the	risk	of	accumulation	of	toxic	
metabolites	(normeperidine)	that	may	cause	seizures,	meperidine	is	
not	recommended	by	our	expert	panel.64
Note:	 Meperidine	 use	 for	 postoperative	 shivering	 is	 not	 ad-
dressed	in	this	recommendation.
Strength of evidence:	B.
8.4 | Use of continuous infusion simultaneous 
with PCA
Randomized	controlled	trials	that	have	compared	continuous	opioid	
infusion	with	PCA	to	PCA	alone	have	suggested	that	the	addition	of	
continuous	 infusion	may	 have	many	 possible	 effects	 on	 the	 over-
all	 impact	 of	 PCA	 therapy.	Comparative	 studies	 of	 6‐12	 year	 olds	
postappendectomy65,66;	 5‐20	 year	 olds	 postelective	 spinal	 fusion	
for	scoliosis67;	school‐age	children	postlower	extremity	orthopedic	
surgery68;	and	6‐15	year	olds	postappendectomy69	 fail	to	show	an	
overall	improvement	in	pain	scores	with	the	addition	of	a	continuous	
infusion.	There	is	evidence	of	an	increase	in	overall	opioid	usage	and	
an	increased	level	of	sedation	with	continuous	infusions.	The	impact	
on	 sleep	has	been	 inconsistent.	 Some	data	 indicate	an	 increase	 in	
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sleep	duration65,66	but	there	has	also	been	documentation	of	an	in-
terruption	of	normal	sleep	patterns	in	a	single‐center	retrospective	
audit	of	126	children.70
In	terms	of	the	risk	of	adding	continuous	infusion	to	PCA,	a	meta‐
analysis	 of	 randomized	 controlled	 trials	 (including	 both	 adult	 and	
pediatric	patients)	 indicated	that	pediatric	patients	have	an	overall	
lower	 risk	of	 serious	 adverse	events	 associated	with	a	 continuous	
infusion	combined	with	PCA	when	compared	 to	 the	adult	popula-
tion.71	This	finding	may	be	confounded	by	routine	use	of	continuous	
respiratory	monitoring	in	the	pediatric	population.72	Another	meta‐
analysis	 examining	 randomized	 controlled	 studies	 comparing	 PCA	
vs	PCA	plus	background	infusion	for	postoperative	children	showed	
no	difference	in	pain	scores,	opioid	consumption,	or	risk	of	adverse	
events	at	12	and	24	hours.73
Recommendation:	There	is	conflicting	and	insufficient	evidence	
to	 indicate	 a	difference	 in	overall	 analgesia,	 sleep	patterns,	or	 ad-
verse	events	with	the	addition	of	continuous	opioid	infusion	to	PCA	
in	children.	Use	of	a	basal	infusion	should	be	individualized	based	on	
consideration	of	the	clinical	situation,	pain	severity,	and	risk	factors.
Strength	of	Evidence:	B.
8.5 | PCA‐by nurse or parent proxy—(Nurse‐
controlled analgesia and parent‐controlled analgesia)
Many	pediatric	patients	are	either	developmentally	or	physically	
unable	 to	 activate	 their	 PCA	 pump	 and	 require	 assistance	 from	
a	 caregiver.	 When	 control	 of	 the	 bolus	 dose	 delivery	 is	 turned	
over	to	a	caregiver,	the	technique	is	referred	to	as	PCA	by	proxy	
(PCA‐P)	 or	NCA.	One	 retrospective	 study	 of	 302	 children	man-
aged	 with	 NCA	 vs	 intermittent	 IV	 dosing	 documented	 similar	
numbers	of	adverse	events	 in	both	cohorts.	This	study	was	con-
founded	by	 the	 fact	 that	 the	NCA	cohort	 tended	 to	be	younger	
and	had	more	medical	co‐morbidities.74	A	prospective	1‐year	ob-
servational	study	of	212	children	undergoing	nurse	or	parent‐con-
trolled	 analgesia	 showed	 these	methods	were	 effective	 for	 pain	
control.	Notably,	 all	 participants	 underwent	 extensive	 standard-
ized	training	in	the	use	of	PCA‐P.	Minor	adverse	events	occurred	
in	4%	of	patients.75	A	 large	 retrospective	 review	of	10	079	chil-
dren	(average	age	4	years)	and	including	510	neonates,	revealed	39	
serious	 adverse	events	 that	 required	 resuscitation	and	naloxone	
administration.	Of	 these	13	were	 infants	 less	 than	3	months	old	
and	four	were	ex‐premature	neonates	and	no	deaths	occurred.76 
Another	study	of	107	preschoolers	and	 infants	utilizing	nurse	or	
parent‐controlled	analgesia	found	1.9%	of	those	patients	had	a	se-
rious	adverse	event	requiring	naloxone	administration.77	NCA	has	
also	been	investigated	in	the	neonatal	intensive	care	unit	(NICU)	in	
a	single	retrospective	study	of	20	infants	compared	to	13	who	had	
fentanyl	continuous	infusions.	The	infants	receiving	NCA	had	ex-
cellent	pain	control	and	a	significantly	 lower	opioid	consumption	
than	 those	 on	 continuous	 infusion	 (84%	 less	 morphine	 equiva-
lents).	There	was	no	difference	in	occurrence	of	adverse	events	or	
in	subsequent	methadone	use.78	One	randomized	controlled	trial	
of	 PCA	vs	PCA	with	 continuous	 infusion	 in	 children	 after	 spinal	
fusion	included	a	subgroup	analysis	that	indicated	nurses	who	per-
formed	NCA	underestimated	patient	pain	as	compared	to	self‐re-
ported	pain	scores	and	administered	less	total	opioid	than	patients	
self‐administering	medication.67
The	use	of	authorized	parent‐controlled	analgesia	has	been	asso-
ciated	with	acceptable	safety	and	effective	postoperative	analgesia	
delivery	for	children	who	are	unable	to	use	PCA	themselves.67,74‐84	A	
dose‐finding	study	of	30	infants	and	toddlers	(6	months	to	2	years	of	
age)	using	parent‐controlled	analgesia	with	fentanyl	after	cleft	palate	
repair	had	no	instances	of	over‐sedation	or	apnea	and	three	patients	
with	vomiting.82
Recommendation:	 There	 is	 evidence	 that	NCA	 and	 parent‐con-
trolled	 analgesia	 is	 associated	 with	 safety	 and	 efficacy	 outcomes	
that	 are	 similar	 to	 that	 of	 standard	 PCA	 therapy.	 These	methods	
must	be	applied	in	an	institutionally	sanctioned	program	with	appro-
priate	training	and	monitoring.
Strength of evidence:	B.
8.6 | PCA adjunctive medications
8.6.1 | Ketorolac
There	 is	 supportive	 evidence	 for	 the	 opioid	 sparing	 effect	 of	 ke-
torolac	 when	 added	 to	 PCA	 analgesia.	 A	 randomized	 controlled	
study	of	68	children	comparing	ketorolac	to	placebo	every	6	hours	
found	better	pain	control	and	a	42%	reduction	in	morphine	admin-
istered	by	PCA	after	PACU	discharge.85	Another	study	of	50	pedi-
atric	patients	found	that	a	single	dose	of	ketorolac	intraoperatively	
was	superior	to	placebo	resulting	in	lower	pain	scores	and	decreased	
PCA	morphine	requirements	in	the	first	12	hours.86	A	case‐control	
study	comparing	29	children	who	received	ketorolac	plus	morphine	
to	 children	who	 received	 only	morphine	 similarly	 found	 an	 opioid	
sparing	 effect	 of	 ketorolac	without	 a	 difference	 in	 side	 effects.87 
A	randomized	controlled	trial	of	35	adolescents	after	spinal	fusion	
found	 lower	 postoperative	 pain	 scores	 and	 decreased	 morphine	
consumption	delivered	by	PCA	when	ketorolac	was	included	in	their	
therapy.88	 There	was	no	evidence	 for	 excessive	bleeding	with	 ke-
torolac	in	any	of	these	studies.
Recommendation:	The	use	of	ketorolac	should	be	strongly	consid-
ered	as	an	adjunct	to	PCA	for	pediatric	perioperative	pain	control.	
Most	 evidence	 available	 for	 nonsterioidal	 anti‐inflammatory	 drug	
(NSAID)	effect	on	PCA	dosing	involves	ketorolac,	however	there	is	
good	 reason	 to	 assume	 another	NSAID	would	 have	 a	 similar	 PCA	
dose	sparing	effect.
Strength of evidence:	A.
8.6.2 | Acetaminophen
There	 is	 supportive	 evidence	 for	 an	 opioid	 sparing	 effect	 when	
acetaminophen	 is	 added	 to	 PCA	 therapy	 in	 pediatric	 patients.	 A	
study	of	80	children	after	appendectomy	showed	a	significant	mor-
phine	sparing	effect	with	diclofenac,	but	a	nonsignificant	effect	(17%	
less)	with	oral	acetaminophen.89	In	contrast,	a	study	of	63	children	
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after	 ureteroneocystostomy,	 compared	 fentanyl	 with	 intravenous	
acetaminophen	 PCA	 to	 fentanyl‐only	 PCA	 found	 that	 pain	 scores	
were	 similar	 between	 the	 groups.	However,	 a	 fentanyl	 sparing	 ef-
fect	 (53%	 reduction)	 was	 observed	 along	 with	 a	 lower	 incidence	
of	 vomiting	 and	 sedation	 in	 the	 fentanyl‐acetaminophen	 group.90 
In	another	study	of	36	children	and	adolescents	after	spinal	fusion	
surgery,	 those	 receiving	 three	postoperative	 doses	of	 intravenous	
acetaminophen	were	compared	to	placebo.	Children	who	received	
acetaminophen	showed	a	 reduction	 in	oxycodone	consumption	as	
administered	by	PCA	and	improved	pain	scores.91
There	is	evidence	that	acetaminophen	is	less	effective	for	neo-
nates	than	older	children,	particularly	for	procedural	pain.92,93
Recommendation:	The	use	of	acetaminophen	should	be	consid-
ered	as	an	adjunct	to	PCA	for	pediatric	perioperative	pain	control.
Strength of evidence:	A.
9  | RECOMMENDATIONS FOR 
OUTPATIENT POSTOPER ATIVE OPIOID USE 
IN CHILDREN
Topics	in	this	section:
•	 What	is	the	role	of	educational	resources?
•	 What	 is	 the	 evidence	 for	 the	 choice	 of	 specific	 opioid	 therapy,	
dosing	strategies	for	outpatient	opioids,	use	of	combined	opioid	
and	benzodiazepine	therapy,	or	the	prescribing	practices	for	opi-
oid	medications	for	outpatients?
9.1 | Educational resources
There	 is	 evidence	 that	 pain	 is	 poorly	managed	 at	 home	 after	 sur-
gery	in	children.94	Data	from	multiple	investigators	indicate	children	
have	been	shown	to	report	significant	pain	after	many	types	of	sur-
geries	 including	tonsillectomy	or	adenotonsillectomy	 (T&A),	dental	
extraction,	and	circumcision.	Studies	suggest	that	parents	may	not	
give	adequate	pain	medications	to	children	for	a	number	of	reasons,	
including	lack	of	information,	inadequate	understanding	of	perioper-
ative	opioid	drug	requirements,	inadequate	or	inappropriate	under-
standing	of	dosing,	uncertainty	over	adverse	drug	effects,	and	child	
refusal.94-96	Poor	understanding	of	opioids	can	lead	some	parents	to	
withhold	opioids	altogether	to	avoid	perceived	risk	or,	conversely,	to	
administer	opioids	when	children	are	excessively	sedated.97,98
Educational	materials	can	take	many	forms.	In	adult	patients	the	
use	 of	 an	 informational	 brochure	 has	 been	 shown	 to	 significantly	
improve	 the	 percentage	 of	 patients	who	 disposed	 of	 unused	 opi-
oid	 pain	 medications	 after	 surgery.99	 For	 children,	 websites	 such	
as	kidshealth.org,	provide	simple,	easy	to	read	answers	to	the	most	
common	questions	parents	have	about	opioids	for	pain	treatment.	
Additional	 links	 are	 included	 to	 provide	 additional	 information	
as	 needed.	 More	 recently	 websites,	 such	 as	 mychi	ldisi	npain.org.
uk,	 combine	 excellent	 graphics	 with	 informative	 text	 and	 video	
presentations	 to	 provide	 up	 to	 date	 information	 on	 how	 parents	
should	approach	pain	management	and	include	specific	information	
on	medication	issues.
Recommendation:	Educational	resources	must	be	provided	to	in-
form	parents	of	the	appropriate	indications	for	pain	medications	and	
strategies	for	the	safe	use	of	opioids,	nonopioids	and	other	measures	
to	manage	 their	 child's	postoperative	pain.	Parents	 should	 receive	
both	 verbal	 and	 written	 detailed	 discharge	 instructions	 regarding	
home	pain	management	with	instructions	regarding	safe	storage	and	
disposal	of	leftover	medications.
Strength of evidence:	C.
9.2 | Specific opioid therapy for outpatients
There	 is	 a	 paucity	 of	 pediatric	 literature	 upon	which	 to	 formulate	
evidence‐based	 recommendations	 for	 opioid	 dosing	 after	 surgery	
and	discharge	home.	One	exception	is	the	strong	evidence	against	
the	use	of	codeine,	particularly	in	children	undergoing	tonsillectomy	
and	for	other	surgeries.100-102	Metabolism	is	variable	with	1%	of	eth-
nic	Northern	Europeans	and	up	to	29%	of	Ethiopians,	experiencing	
ultra‐rapid	metabolism	of	codeine	to	morphine.	This	results	in	high	
morphine	 levels	 even	 after	 standard	 codeine	 doses.	On	 the	 other	
hand,	approximately	10%	of	patients	 lack	the	ability	to	metabolize	
codeine	to	morphine	and	therefore	experience	little	analgesic	ben-
efit	from	this	drug.
Similarly,	 tramadol	 is	a	prodrug	metabolized	by	enzyme	com-
plexes	CYP3A4	and	predominantly	2D6.	Like	codeine,	 there	can	
be	ultra‐rapid	metabolizers	for	CYP2D6	 leading	to	apnea.	 It	also	
carries	a	risk	of	seizures.103,104	There	is	a	common	misunderstand-
ing	 that	 it	 is	 a	 safer	 alternative	 to	 opioids.7	 The	FDA	has	 issued	
a	warning	concerning	the	use	of	tramadol	that	advises	restricted	
use	in	children	younger	than	18	years	after	tonsillectomy,	children	
younger	 than	12	years	of	 age,	 and	 adolescents	between	12	 and	
18	years	who	are	obese,	have	obstructive	sleep	apnea	 (OSA),	or	
lung	disease.105,106
Recommendation:	 Codeine	 should	 be	 avoided	 in	 children	 and	
nursing	 mothers	 as	 a	 postoperative	 analgesic.	 This	 is	 particularly	
true	if	they	have	symptoms	of	obstructive	sleep	apnea	or	sleep	dis-
ordered	breathing.
Strength of evidence:	A.
Recommendation:	There	is	evidence	to	advise	against	the	use	of	
tramadol	 for	specific	populations	of	pediatric	patients,	particularly	
young	patients	(under	12)	and	those	with	OSA.
Strength of evidence:	B.
9.3 | Dosing strategies
There	are	only	two	randomized	prospective	studies	evaluating	the	
appropriate	dosing	of	opioids	in	postoperative	pediatric	patients.	In	
one	study,	Sutters	et	al	compared	“around	the	clock”	(ATC)	dosing	to	
an	“as	needed”	administration	(PRN)	strategy.	In	this	case,	children	
who	 received	 ATC	 acetaminophen	 with	 hydrocodone	 were	 com-
pared	to	those	who	received	the	same	medications	“as	needed”	for	
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complaints	of	pain.107	There	was	improved	pain	control	in	the	ATC	
cohort,	but	a	slightly	higher	 incidence	of	complications	 including	a	
higher	rate	of	daytime	sedation	in	this	group.	A	Cochrane	review	of	
ATC	vs	“as	needed”	dosing,108	 including	three	RCTs	with	a	total	of	
246	children	aged	under	16	years	of	age	found	more	medication	is	
administered	 in	the	ATC	group,	but	were	unclear	as	to	whether	or	
not	pain	management	was	improved.
Recommendation:	 There	 is	 insufficient	 evidence	 to	 recommend	
PRN	vs	scheduled	dosing	strategies	for	opioids	after	surgery	in	chil-
dren.	Expert	 consensus	 is	 to	use	a	PRN	strategy	until	 further	evi-
dence	is	available.
Strength of evidence:	C.
9.4 | Combinations of opioids and benzodiazepines
A	recent	FDA	review	determined	that	the	use	of	opioid	medications	
in	 combination	with	 benzodiazepines	 in	 adults	 has	 increased,	 and	
that	this	practice	has	resulted	in	serious	side	effects.109	Two	stud-
ies	are	highlighted	in	this	statement.	The	first	found	that	the	num-
ber	of	opioid	analgesic	prescriptions	 increased	8%	and	 the	annual	
number	of	benzodiazepine	prescriptions	increased	by	31%	over	the	
last	5	years.110	 The	number	of	patients	 receiving	overlapping	pre-
scriptions	for	these	two	medications	has	increased	by	41%.	The	sec-
ond	 study	 found	 that	 between	2004	 and	2011	 the	 rate	 of	 opioid	
overdose	 deaths,	 in	 which	 benzodiazepines	 were	 also	 implicated,	
increased	 from	18%	 to	31%.111	However,	no	 similar	pediatric	data	
have	been	reported.
Recommendation:	 Opioid	 pain	 medications	 should	 not	 be	 pre-
scribed	with	benzodiazepines	except	in	children	for	whom	there	is	a	
specific	indication	and	alternative	treatment	options	are	inadequate.	
Doses	 should	be	 limited	 to	 the	 lowest	 effective	 level	 and	parents	
should	be	warned	about	the	potential	for	excessive	sedation	and	re-
spiratory	depression.
Strength of evidence:	C.
9.5 | Opioid prescribing
Several	 federal	 agencies	 and	 physician	 organizations	 (Centers	
for	Disease	Control	 [CDC],	 Substance	Abuse	 and	Mental	Health	
Services	Administration	[SAMHSA],	American	Medical	Association	
[AMA])	 have	weighed	 in	 on	 the	 over	 prescription	 of	 opioids	 for	
postoperative	 patients.	 These	 organizations	 highlight	 the	 grow-
ing	incidence	of	opioid	overdose	in	pediatric	patients,	particularly	
teenagers.	 The	 most	 common	 source	 of	 prescription	 opioids	 is	
drug	 supplies	 from	 leftover	 prescriptions	 (family,	 friends,	 neigh-
bors,	 etc)	 where	 opioid	 prescriptions	 were	 overly	 generous	 in	
order	to	avoid	any	possible	requirement	for	refilling	prescriptions.	
Recent	 studies	 have	 found	 children	 are	 prescribed	 amounts	 of	
opioids	that	significantly	exceed	the	total	administered	at	home.	
Parents	 rarely	 received	 instructions	 regarding	 safe	 disposal	 of	
leftover	opioids.112
Recommendation:	Opioid	prescriptions	should	be	limited	to	that	
required	for	the	expected	period	of	severe	pain	after	surgery	(local	
laws	may	set	limits	for	quantity	or	time	parameters	for	opioid	pre-
scriptions).	Patients	should	be	educated	concerning	the	appropriate	
storage	and	disposal	of	opioids.
Strength of evidence:	B.
10  | OPIOID TRE ATMENT OF THE PATIENT 
WITH CHRONIC PAIN SCHEDULED FOR 
MA JOR SURGERY
Topics	in	this	section:
•	 What	are	the	strategies	for	providing	analgesia	for	patients	with	
chronic	pain?
•	 How	 do	 we	 approach	 analgesia	 for	 patients	 with	 central	
sensitization?
Many	 pediatric	 patients	 present	 for	 surgery	 with	 a	 history	 of	
chronic	 pain,	 be	 it	 pain	 related	 to	 “central	 sensitization”,113 
cancer	 pain,114	 chronic	 orthopedic	 conditions	 or	 other	 medi-
cal	 issues.115	Some	of	these	children	will	be	opioid	dependent	
or	 tolerant	 due	 to	 their	 treatment	with	 these	medications	 on	
a	long‐term	basis.	Furthermore,	pediatric	patients	with	chronic	
pain	who	are	on	 long	acting	or	partial	 agonist	opioid	 therapy,	
including	 methadone	 or	 buprenorphine,	 require	 special	 con-
sideration.116	There	is	little	evidence	to	guide	the	treatment	of	
these	patients,	 but	 experience	 and	 reason	demands	 a	 flexible	
and	multimodal	approach.117
It	is	critical	to	differentiate	certain	terms	associated	with	chronic	opi-
oid	use.	Physical	dependence	describes	the	alterations	in	physiologic	
response	that	result	from	opioid	binding	and	receptor‐mediated	activ-
ity.	In	this	subgroup,	sudden	discontinuation	of	opioids	leads	to	opioid	
withdrawal	 or	 abstinence	 syndrome.	Opioid	 tolerance	 refers	 to	 the	
pharmacologic	adaptation	that	occurs	after	chronic	exposure	to	opi-
oids	where	there	is	a	shift	in	the	dose‐response	curve	and	patients	re-
quire	increasing	amounts	of	drug	to	maintain	the	same	pharmacologic	
effects.	Finally,	drug	addiction	refers	to	a	complex	phenomenon	where	
the	use	of	a	drug	becomes	the	central	point	of	focus	for	the	user's	life	
(ie,	deriving	psychological	reward	other	than	analgesia)	even	in	the	face	
of	obvious	physical	or	psychological	harm.	Patients	who	exhibit	addic-
tion	are	usually	physically	dependent	on	an	opioid.	Dependence	and	
addiction	may	exist	in	conjunction	with	each	other	or	as	independent	
entities	and	must	be	identified	and	appreciated	in	order	to	appropri-
ately	(and	safely)	treat	pain	in	this	challenging	population.118
10.1 | Perioperative care of patients with chronic 
pain disorders who are taking opioids
Recommendations	for	pediatric	patients	presenting	for	surgery	who	
are	on	opioids	for	chronic	pain	syndromes	are	entirely	extrapolated	
from	the	adult	literature.	There	is	a	single	observational	study	show-
ing	 that	pediatric	patients	previously	placed	on	opioid	 infusions	 in	
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an	 intensive	 care	 unit	 do	 not	 have	 increased	 perioperative	 opioid	
requirements	if	they	have	previously	been	successfully	weaned	off	
the	opioids.119
In	the	adult	literature,	recommendations	for	perioperative	man-
agement	of	 patients	with	 chronic	 pain	 using	opioids	 are	 based	on	
case	reports,	common	sense,	or	consensus	rather	than	randomized	
studies.	Although	not	scientifically	tested,	these	recommendations	
have	been	advocated	in	the	setting	of	receptor	down‐regulation	and	
appreciation	of	the	physiological	and	psychological	changes	that	ac-
company	chronic	pain	and	opioid	treatment.	 In	all	cases,	perioper-
ative	care	is	advised	to	begin	with	preoperative	administration	and	
continuation	of	 the	daily	maintenance	 (or	baseline)	opioid	dose.120 
Additional	doses	of	opioid	should	be	titrated	 intra‐operatively	and	
postoperatively	to	provide	effective	postsurgical	analgesia	in	addi-
tion	to	covering	the	baseline	requirements.118	Dosing	guidelines	are	
not	 available,	 but	 requirements	 to	meet	 postsurgical	 analgesic	 re-
quirements	are	affected	by	receptor	down‐regulation	and	may	need	
to	be	 increased	three	to	10	times	of	 that	 required	by	opioid	naïve	
patients.121,122	Continuous	opioid	infusion	or	patient‐controlled	an-
algesia	(PCA)	techniques	are	useful	options	in	this	subgroup.
While	 these	 recommendations	will	 not	 review	 adjunctive	 pain	
medication	use	in	detail,	 it	 is	 important	to	note	that	multiple	stud-
ies	in	children	support	adjunctive	therapies	such	as	nonopioid	pain	
relievers	 (acetaminophen,	 nonsteroidal	 ant	 inflammatory	 agents,	
gabapentin,	 tricyclic	 antidepressants),	 and/or	 regional	 anesthesia	
techniques	to	improve	pain	control	for	chronic	pain	patients	under-
going	surgery.117	In	pediatric	patients	the	use	of	multimodal	analge-
sic	 treatment	 results	 in	 decreased	 episodes	 of	 substantial	 pain.123 
In	addition,	nonpharmacological	interventions	such	as	acupuncture	
and	massage	 therapy	have	been	 shown	 to	be	 effective	 in	 amelio-
rating	pain	after	surgery	and	decreasing	chronic	pain	symptoms	 in	
children.124,125	 Alternative	 medications	 such	 as	 dexmedetomidine	
and	low	dose	ketamine	(1‐5	mcg/kg/h)	have	been	successfully	em-
ployed	as	adjuvant	therapy	in	pediatric	patients	with	severe	chronic	
pain.126,127	It	is	also	worthwhile	to	consider	the	contributions	of	fear,	
anxiety,	and	depression	to	opioid	consumption.	These	issues	should	
be	discussed	transparently	and	treated	with	psychological	and	phar-
macological	interventions	as	indicated	on	a	case	by	case	basis.117
Recommendation:	 For	 pediatric	 patients	with	 chronic	 pain	who	
are	maintained	on	opioids,	continue	established	preoperative	dosing	
during	the	perioperative	period	as	a	baseline.	Acute	postsurgical	an-
algesia	should	be	provided	over	and	above	the	baseline	opioids.	Use	
of	 nonopioid	 analgesia	 is	 encouraged	 including	 regional	 analgesia	
techniques,	alpha‐2	agonists,	ketamine,	acetaminophen,	nonsteroi-
dal	anti‐inflammatory	drugs,	and	neuropathic	pain	medications	such	
as	gabapentinoids	or	antidepressants.
Strength of evidence:	C.
Recommendation:	If	the	patient	with	chronic	pain	on	chronic	opi-
oid	therapy	undergoes	a	procedure	that	is	 intended	to	remove	the	
source	of	the	patient's	pain,	they	should	be	monitored	for	over	seda-
tion	and	should	be	discharged	home	with	a	defined	opioid	weaning	
plan.	Opioid	weaning	in	this	case	should	be	managed	by	a	physician	
with	special	training	or	expertise	in	pain	medicine.	Limited	supplies	
of	opioids	should	be	prescribed	and	refilled	at	frequent	intervals	that	
include	face‐to‐face	follow	up	visits.
Strength of evidence:	C	(based	on	extrapolation	of	adult	data	and	
expert	consensus).
Recommendation:	 If	 a	patient	with	chronic	pain	on	opioid	 ther-
apy	undergoes	surgery	and	the	patient's	underlying	pain	source	was	
independent	of	the	surgery,	the	patient's	baseline	pain	should	con-
tinue	to	be	managed	by	the	physician	who	had	been	doing	so	pre-
operatively.	Opioid	analgesics	for	the	perioperative	pain,	if	needed,	
should	be	prescribed	in	limited	quantities	consistent	with	the	degree	
of	physiologic	trespass.
Strength of evidence:	C	(based	on	extrapolation	of	adult	data	and	
expert	consensus).
10.2 | Patients with central sensitization
Perioperative	pain	management	 for	pediatric	patients	with	central	
sensitization	 is	 largely	based	on	 consensus.	 In	 the	pediatric	popu-
lation	 the	cohort	 is	 largely	made	up	of	patients	with	 fibromyalgia,	
former	premature	newborns	with	extensive	procedure	history	from	
the	 intensive	 care	 nursery,	 those	 with	 cancer,	 and	 those	 with	 an	
extensive	 surgical	 history.	 These	 patients	 are	 characterized	 by	 in-
creased	sensitivity	to	painful	or	nonpainful	stimuli.	There	is	evidence	
in	adults	with	fibromyalgia	that	they	are	at	risk	for	increased	acute	
and	chronic	postoperative	pain.128,129
Recommendation:	For	pain	management	of	patients	with	central	
sensitization—strategies	should	be	similar	to	those	for	pediatric	pain	
patients	 on	 chronic	 opioids	 (use	 nonopioid	 analgesic	 techniques	
to	 the	 greatest	 extent	 possible).	 Opioids	 should	 be	 prescribed	 as	
needed.	These	patients	benefit	from	the	involvement	of	a	pain	phy-
sician	for	the	purposes	of	assuring	appropriate	use	and	discontinua-
tion	of	medications	in	a	reasonable	time	frame.
Strength of evidence:	C.
11  | A SSESSMENT OF PAIN AND 
ANALGESIC EFFIC ACY
Topics	covered	in	this	section:
•	 How	should	we	assess	pain	intensity?
•	 Is	there	evidence	for	pain	behavior	observation,	assessing	the	re-
sponse	to	treatment,	postoperative	recovery	and	function?
Pediatric	 anesthesiologists	 are	 routinely	 asked	 to	 assist	 in	 periop-
erative	pain	management,	and	there	 is	wide	agreement	that	ap-
propriate	assessment	of	pain	is	necessary	in	order	to	better	guide	
care	 during	 the	 perioperative	 and	 postoperative	 period.2,130‐132 
Unfortunately,	 there	 are	 insufficient	 data	 to	 support	 the	 bene-
ficial	effect	of	 routine	pain	assessment	on	patient	outcomes.133 
Furthermore,	 observational	 data	 evaluating	 institutional	 prac-
tices	 demonstrate	 inconsistencies	 in	 the	 frequency	 and	 nature	
of	pain	assessment	in	many	hospital	settings.134-137	Inappropriate	
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assessment	 and/or	misinterpretations	 of	 pain	 assessments	may	
lead	to	under‐	or	over‐use	of	analgesics	and	suboptimal	or	even	
harmful	outcomes.138-140	Consensus	documents	addressing	pain	
management	in	children	recommend	that	assessment	of	a	child's	
pain	 should	 be	 multi‐dimensional	 (location,	 nature,	 intensity),	
developmentally	guided,	and	include	the	use	of	well‐established	
instruments	(those	with	at	least	two	peer	reviewed	studies	by	dif-
ferent	teams	that	have	established	reliability	and	validity).2,130‐132 
It	is	also	recommended	that	pain	assessments	(including	use	and	
interpretation	of	pain	intensity	scores)	be	made	in	consideration	
of	the	unique	situational	context	(eg,	type	and	nature	of	surgery),	
treatments	received,	and	psycho‐social	factors.141-143
Recommendation:	 Regular	 pain	 assessments	 should	 be	 part	 of	 the	
perioperative	care/treatment	of	pediatric	patients	who	are	receiving	
opioid	 medications.	 These	 assessments	 should	 be	 made	 using	 vali-
dated	measures.	The	pain	assessment	should	consider	the	unique	cir-
cumstances	of	the	child's	psychological	state	and	the	extent	of	surgery.
Strength of evidence:	B.
11.1 | Self‐report measures
Observational	studies	demonstrate	children	greater	than	4	years	of	
age	 can	 reliably	use	 self‐report	 instruments	 to	describe	and	 score	
pain	 intensity.	However,	children	 less	than	8	years	of	age	have	ex-
hibited	difficulty	distinguishing	between	sensory	pain	(eg,	incisional	
pain,	and	distress	or	affect,	ie	fear),132,144	and	often	exhibit	scoring	
biases.145	Additionally,	young	children	aged	four	to	eight	have	been	
observed	 giving	 differing	 pain	 scores	 to	 different	 people	 during	 a	
painful	procedure.146	There	is	insufficient	evidence	to	know	whether	
older	children	or	adolescents	exhibit	scoring	biases.
Systematic	reviews	and	consensus	panels	have	identified	several	
self‐report	measures	 that	 are	 considered	well	 established	 in	mea-
suring	pain	intensity	during	procedures,	after	surgery,	and	for	use	in	
clinical	analgesic	trials.147,148	These	include	(but	are	not	limited	to)	the	
0‐10	Numeric	Rating	Scale	 (NRS),	Faces	Revised	Pain	Scale	 (FRPS),	
and	the	color	analog	scale.	It	is	widely	recommended	by	consensus	
groups	a	self‐report	of	pain	 intensity	be	obtained	whenever	possi-
ble	to	assess	and	document	the	child's	perceived	level	of	pain	inten-
sity130,131,149	and	that	behavioral	observation	be	used	to	complement	
self‐report,	particularly	when	scores	are	inconsistent	with	the	clinical	
presentation,	contextual	factors,	or	appear	to	be	biased.130,140
Several	 observational	 studies	 have	 reported	 average	 self‐re-
ported	 numeric	 or	 faces	 pain	 intensity	 scores	 children	 associate	
with	 perceptions	 of	 pain	 severity	 and	 their	 need	 for	 analgesia	 (ie,	
in	general,	higher	scores	are	more	often	associated	with	perceived	
need).142	However,	wide	variability	has	been	observed	in	children's	
pain	perceptions	and	reported	population	averages	may	not	reflect	
the	needs	of	the	individual	child.	Pain	intensity	scores	must	there-
fore	be	 interpreted	 in	context.	For	 instance,	 studies	 that	based	 ti-
tration	of	opioid	doses	on	specific	pain	scores	 (most	commonly	 to	
achieve	a	 score	of	 less	 than	 four	out	of	 ten)	have	 resulted	 in	high	
rates	 of	 excessive	 sedation.150	 Other,	 more	 global	 comfort	 and	
function	outcomes	(ability	to	take	a	deep	breath	and	cough,	get	out	
of	 bed,	 etc),	 are	more	 nebulous	 but	 better	 indicators	 of	 analgesic	
need	compared	to	arbitrary	target	pain	scores.
Recommendation:	Pain	intensity	scores	can	be	used	to	assess	
a	 child's	 perceived	 degree	 of	 discomfort.	 However,	 decisions	 to	
administer	analgesics	should	take	into	consideration	patient	func-
tional	 behaviors,	 situational	 factors	 such	 as	 pain	 source,	 self‐re-
ported	 pain	 scores,	 parental	 observation,	 and	 other	 potential	
sources	 of	 distress,	 rather	 than	 arbitrarily	 selected	 pain	 score	
cutoffs.
Strength of evidence:	B.
11.2 | Behavioral observation
Behavioral	 observation	 instruments	 can	 be	 reliably	 used	 to	 docu-
ment	 pain	 behaviors	 in	 children	who	 cannot	 self‐report,	 including	
those	younger	than	4	years	of	age,	 infants,	neonates,	and	children	
or	 adolescents	 with	 moderate	 to	 severe	 cognitive	 impairments.	
Observational	 studies	 have	 demonstrated	 behavioral	 observation	
instruments	 can	 be	 used	 reliably	 between	 providers	 to	 document	
pain	behaviors.149,151,152	These	measures	include	(but	are	not	limited	
to):
•	 Behavior	 and	 posture‐related	 scales	 (Faces,	 Legs,	 Activity,	 Cry,	
Consolability	 [FLACC],	 Children's	 Hospital	 of	 Eastern	 Ontario	
Pain	Scale	[CHEOPS])
•	 Combined	 behavioral/physiologic	 parameter	 scales	 (Crying,	
Requires	O2,	Increased	Vital	Signs,	Expression,	Sleepless	[CRIES])
Observational	evidence	also	suggests	behavioral	pain	scores	are	mod-
erately	consistent	with	nurses’	and	parents’	global	assessments	when	
assessing	 pain	 in	 children	 who	 cannot	 self‐report.	 Observed	 pain	
behaviors	 correlate	 significantly	 but	 not	 consistently	with	 children's	
self‐report.149
There	is	insufficient	evidence	that	behavioral	observation	instru-
ments	can	differentiate	pain	distress	from	other	sources	of	distress	
such	as	physiologic	compromise	or	fear.152,153	Thus,	consensus	pub-
lications	 recommend	 behavioral	 observation	measures	 be	 used	 to	
assess	presence	and	intensity	of	pain	in	children	who	cannot	self‐re-
port,	but	also	those	scores	be	interpreted	with	caution	and	in	consid-
eration	of	the	situational	context	and	other	factors.
Recommendation:	Behavioral	observation	can	be	used	to	assess	
pain‐related	distress	in	children.	Directions	to	administer	analgesics	
in	children	who	cannot	self‐report	should	take	into	consideration	sit-
uational	factors	such	as	pain	source,	observational	pain	scores,	and	
other	potential	 sources	of	distress,	 rather	 than	arbitrarily	selected	
pain	score	cut‐offs.
Strength of evidence:	B.
11.3 | Analgesic responsiveness
Data	from	observational	and	clinical	trials	of	analgesics	have	dem-
onstrated	that	self‐report	and	behavioral	observation	pain	intensity	
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scores	are	sensitive	in	detecting	pain	relief	after	analgesic	adminis-
tration	and	over	time	(ie	scores	decrease	significantly	after	admin-
istration).154-160	 Observational	 studies	 have	 also	 reported	 “Mean	
Clinically	 Significant	 Differences”	 in	 that	 the	 average	 decrease	 in	
pain	score	reflects	perceived	pain	relief	 for	children	as	young	as	6	
and	8	years.157,161	On	average,	a	decrease	of	one	point	on	the	0‐10	
NRS	is	associated	with	a	child's	perception	of	pain	relief.	However,	
the	data	show	wide	variability	and	 inconsistencies	 in	reporting	 (eg	
some	scores	go	up	when	the	child	reports	relief	and	these	are	not	
stable	across	pain	intensity	ratings).
Recommendation:	Changes	in	pain	scores	should	be	used	in	con-
junction	with	other	verbal/behavioral	measures	as	indicators	of	pain	
relief	and	analgesic	response	(eg	side	effects)	when	making	analgesic	
decisions.
Strength of evidence:	B.
11.4 | Physiologic measures
Although	an	acute	pain	insult	can	induce	changes	in	physiologic	vital	
sign	parameters	such	as	heart	rate	and	blood	pressure,	observational	
data	have	shown	that	these	changes	are	nonspecific	and	poor	sen-
sitivity	 pain	 indicators.162,163	 Recent	 data	 have	 demonstrated	 cor-
relation	between	high	frequency	heart	rate	variability,	known	as	the	
Analgesia	Nociception	Index	(ANI),	and	observed	FLACC	scores	in	a	
small	sample	of	children.	The	data	suggest	that	an	objective,	physio-
logic,	indicator	of	pain	based	on	parasympathetic	tone	may	be	useful	
for	children	who	cannot	self‐report	pain.156	Such	data	are	relatively	
sparse,	and	the	clinical	usefulness	of	this	tool	remains	to	be	proven.
Recommendation:	Physiologic	parameters	should	be	used	to	as-
sess	the	child's	nociceptive	response	when	it	is	not	possible	to	assess	
pain	with	self‐report	of	behavioral	measures	 (eg,	when	the	child	 is	
sedated	or	is	receiving	neuromuscular	blockers).	It	is	recommended	
that	 other	 potential	 sources	 of	 physiologic	 distress	 (eg,	 emotional	
distress,	 hypovolemia,	 fever,	 hypercarbia)	 be	 considered	 and/or	
ruled	out	when	making	treatment	decisions.
Strength of evidence:	B.
11.5 | Postoperative recovery and function
Consensus	opinion	supports	assessment	of	the	child's	physical	func-
tioning	when	assessing	recovery	from	pain	and	surgery,	yet	there	is	
insufficient	evidence	regarding	valid	or	reliable	measures	to	assess	
children's	physical	 function	 related	 to	acute	postoperative	pain.147 
Pain	 interference	 instruments	categorize	the	degree	to	which	pain	
hinders	engagement	with	social,	cognitive,	emotional,	physical,	and	
recreational	activities.	Observational	data	support	the	reliability	of	
parental	functional	assessment	of	the	child's	pain	interference	after	
surgery.164,165	Pain	interference	also	incorporates	items	that	address	
ability	to	sleep	and	school	attendance.	These	tools	are	available	for	
adults	and	pediatric	self‐reporters	as	well	as	a	version	where	parents	
serve	as	proxy	reporters.
Recommendation:	 A	 child's	 functional	 recovery	 should	 be	 as-
sessed	to	inform	treatment	plans.
Strength of evidence:	C.
11.6 | Nature and location of pain
Observational	 studies	 have	 demonstrated	 children	 as	 young	 as	
4	years	can	reliably	identify	a	pain	location	(ie	body	map)	that	is	con-
sistent	with	clinical	 findings.166,167	Additionally,	observational	data	
suggest	 that	 children	as	young	as	8	years	of	 age	can	describe	 the	
quality	and	nature	of	pain	using	word	lists	and	scales.168
Recommendation:	 Assessing	 pain	 location	 is	 recommended	 to	
differentiate	incisional	pain	from	other	potential	sources	of	postop-
erative	pain.	The	nature	of	pain	should	be	assessed	to	assist	in	the	
differentiation	of	pain	type.
Strength of evidence:	B.
12  | MONITORING OF PATIENTS ON 
PERIOPER ATIVE OPIOID THER APY
Topics	covered	in	this	section:
•	 How	should	we	utilize	physiologic	assessment	of	pain?
•	 Is	there	a	strategy	for	monitoring	sedation	from	opioids?
•	 What	is	the	role	of	the	institution	in	monitoring	practice?
Because	of	variability	 in	both	efficacy	and	adverse	effects	of	opi-
oid	analgesics	among	pediatric	patients	in	the	immediate	postop-
erative	 time	period	monitoring	 (through	 technology	and	human	
observation)	should	include	vital	signs	and	level	of	sedation	to	as-
sess	adverse	effects	of	opioids.	The	ASA,	the	Anesthesia	Patient	
Safety	 Foundation	 (APSF),	 the	 Joint	 Commission,	 Centers	 for	
Medicare	 and	Medicaid	Services	 (CMS),	 and	 the	American	Pain	
Society	(APS)	have	promulgated	practice	guidelines	incorporating	
the	recommendations	for	monitoring	discussed	below.8,169‐173
12.1 | Physiologic monitoring
There	 are	no	prospective	 randomized	 trials	 investigating	 the	mini-
mum	monitoring	requirements	concerning	pediatric	patients	on	PCA	
opioid	 infusions.	Additionally,	 there	are	no	clinical	 trials	correlating	
levels	of	monitoring	with	 significant	 adverse	outcomes.	 In	 spite	of	
this,	a	national	survey	of	members	of	SPA,	representing	252	institu-
tions	 in	 the	United	 States,	 showed	90%	of	 pediatric	 anesthesiolo-
gists	monitored	patients	on	PCA	with	continuous	pulse	oximetry.72 
Consensus	documents	 and	expert	opinion	 advise	basic	monitoring	
of	respiratory	and	cardiovascular	status	to	recognize	hypoventilation	
and	apnea,	particularly	for	those	who	are	naïve	to	the	drug	and	mo-
dality.79,172‐175	Experts	agree	physiologic	monitoring	of	pediatric	pa-
tients	receiving	initial	doses	of	parenteral	opioids	or	opioids	by	PCA/
NCA/PCA‐P	(parent	and	proxy)	and/or	constant	infusion	should	in-
clude	 respiratory	 rate	 (by	 plethysmography	 or	 direct	 observation),	
and	continuous	pulse	oximetry.	Although	it	is	a	sensitive	measure	of	
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hypoventilation,	capnography	 is	not	 routinely	 recommended,	how-
ever	 its	 use	 has	 been	 described.176-179	 To	 date,	 capnography	 has	
been	shown	to	be	largely	impractical	in	children	in	the	postoperative	
setting.175
Transcutaneous	PaCO2	monitors	have	been	evaluated	in	pediat-
ric	populations,180	 including	a	combined	transcutaneous	oximeter/
carbon	dioxide	monitor.181	Unfortunately,	none	of	these	have	been	
evaluated	in	infants	and	children	receiving	opioid	medications	(spe-
cifically)	in	the	postoperative	setting.
New	 technologies,	 such	 as	 respiratory	 volume	 monitoring,182 
and	detection	of	 expired	 gas	moisture	or	 temperature,	 have	been	
described,	but	have	not	been	tested	or	validated	in	children	for	mon-
itoring	opioid	effects.
Although	 there	 are	 no	 studies	 to	 specifically	 differentiate	 the	
monitoring	 requirements	 for	 populations	 that	 are	 logically	 at	 in-
creased	risk	for	opioid	associated	respiratory	depression,	additional	
vigilance	is	recommended	in	such	patients.	These	populations	include:
1.	 Neonates	 (because	 of	 immaturity	 of	 respiratory	 control	 mech-
anisms	 as	 well	 as	 drug	 metabolism	 and	 clearance)
2.	 Patients	with	cerebral	palsy	(poor	coordination	of	airway	muscu-
lature,	increased	secretions)
3.	 Patients	 with	 neuromuscular	 diseases	 (weakness	 of	muscles	 of	
respiration	[chest	wall]	and	airway	musculature)
4.	 Patients	with	cognitive	impairment	(difficult	assessment	of	pain,	
sedation,	level	of	consciousness)
5.	 Patients	with	 sleep	 disordered	 breathing	 and	 obstructive	 sleep	
apnea	patients	(related	to	anatomic	abnormalities	such	as	Pierre‐
Robin,	obesity,	tonsil‐adenoid	hypertrophy)
6.	 Patients	receiving	poly‐pharmacy	(co‐administration	of	benzodi-
azepines	and/or	sedatives)182,183
7.	 Patients	who	have	had	an	increase	in	PRN	bolus	dose	or	PCA	dose	
of	opioid,	or	addition	of	basal	infusion	rate	to	PCA
8.	 Opioid	 naïve	 patients	 (particularly	 on	 the	 first	 postoperative	
night)
9.	 Patients	 on	 supplemental	 oxygen	 (which	 impairs	 the	 sensitiv-
ity	and	response	time	of	pulse	oximetry	as	a	monitor	for	apnea/
hypopnea)
10.	Patients	receiving	neuraxial	opioids.
Meta‐analysis	of	adult	 studies	has	shown	the	 risk	of	 respiratory	de-
pression	 to	 be	 similar	 between	 "as	 needed"	 bolus	 administration	 of	
opioid	and	PCA	bolus	administration.184
Recommendation:	 Physiologic	monitoring	 of	 children	 receiving	
initial	 intravenous	 opioid	 treatment	 should	 include	 pulse	 oxime-
try	 for	 the	 first	24	hours	unless	 the	patient	 is	 awake	and	actively	
being	 observed.	 Continuous	 monitoring	 of	 respiratory	 rate	 and	
electrocardiogram	 should	 be	 considered	 in	 pediatric	 patients	who	
are	on	oxygen,	or	who	have	risk	factors	for	respiratory	depression.	
Physiological	 monitoring	 may	 be	 suspended	 when	 the	 patient	 is	
alert,	awake,	and/or	ambulating.
Strength of evidence:	C.
Recommendation:	Although	not	specifically	addressed	in	the	lit-
erature,	the	expert	panel	recommends	frequent	assessment	of	the	
quality,	as	well	as	the	rate	of	respirations,	should	be	performed	by	
direct	 observation	 and	 recorded	 in	 the	medical	 record.	 Increased	
frequency	 and	 intensity	 of	 these	 observations	 is	 recommended	
for	 children	 in	 high‐risk	 groups	 in	 addition	 to	 standard	 electronic	
monitoring.
Strength of evidence:	C.
12.2 | Monitoring patients with obstructive 
sleep apnea
Of	all	the	populations	outlined	above,	the	most	commonly	encoun-
tered	 and	well	 studied	 is	 the	 growing	 cohort	 of	 pediatric	 patients	
with	sleep	apnea.	Brown	et	al185	prospectively	studied	the	effects	
of	 pediatric	 recurrent	 desaturation	 events	 on	 sensitivity	 to	 the	
respiratory	depressant	effects	of	morphine	in	20	children	with	ob-
structive	 sleep	 apnea.	Having	previously	 determined	 an	 increased	
risk	 in	 those	with	a	nighttime	oxygen	saturation	nadir	of	<85%,106 
the	 patients	 were	 grouped	 into	 severe	 or	 moderate	 sleep	 apnea.	
Those	with	severe	obstructive	sleep	apnea,	as	measured	by	low	oxy-
gen	nadir,	were	more	sensitive	to	morphine	respiratory	depression	
and	required	a	 lower	total	dose	of	morphine	for	pain	management	
post	tonsillectomy	than	those	with	mild	sleep	apnea.	These	patients	
should	have	their	dose	of	opioid	reduced	by	50%	to	67%	in	addition	
to	requiring	additional	monitoring	in	the	perioperative	period	when	
opioids	are	being	administered.186	The	increased	risk	of	postopera-
tive	 respiratory	 depression	 is	 also	 seen	 in	 adults	with	 obstructive	
sleep	apnea.187
Obesity	 is	 strongly	 associated	 with	 obstructive	 sleep	 apnea.	
Sleep	 apnea	 is	 also	 more	 common	 in	 certain	 pediatric	 popula-
tions	 including	 African	 Americans,	 Hispanic	 Americans,	 prema-
ture	 babies,	 toddlers	who	 attend	 daycare,	 and	 children	 of	 lower	
socioeconomic	 status.186	 Of	 these,	 African	 American	 and	 syn-
dromic	 patients	 had	 the	 greatest	 risk	with	 one	 study	 document-
ing	an	incidence	12.5	and	11	times	that	of	the	baseline	Caucasian	
population.188,189
Some	 adverse	 respiratory	 events	may	 be	 traced	 to	 inaccurate	
dosing	due	to	obesity.	Specifically	opiate	dosing	based	on	total	body	
weight	can	result	in	dangerous	respiratory	depression.190,191	Dosing	
should	be	based	on	ideal	or	lean	body	mass	that	can	be	calculated	
using	one	of	many	dosing	scalers	rather	than	rough	estimates	of	ap-
propriate	weight	dosing.186
Recommendation:	 Patients	 with	 obstructive	 sleep	 apnea,	 obe-
sity	 (>95	percentile	BMI),	 and	 recurrent	 nighttime	oxygen	desatu-
rations	are	at	higher	risk	for	opioid	induced	respiratory	depression.	
Opioid	dosing	should	be	based	on	ideal	or	lean	body	weight	and	the	
dose	of	opioid	should	be	reduced	by	50%	to	67%	for	OSA	patients.	
Additionally,	extended	respiratory	monitoring	is	required	when	opi-
oids	are	being	administered	to	this	population	in	the	perioperative	
period.
Strength of evidence:	B.
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12.3 | Monitoring level of sedation
Excessive	sedation	has	been	found	to	predict/precede	opioid‐related	
respiratory	 depression	 and	 was	 observed	 prior	 to	 opioid‐related	
death/neurological	 injury	 in	 a	 majority	 of	 children.182	 Therefore,	
patients	receiving	PCA	or	PCA‐P,	with	or	without	a	basal	 infusion,	
should	 be	 monitored	 for	 their	 level	 of	 sedation.	 Sedation	 scales	
developed	and	validated	for	use	in	children	undergoing	procedural	
sedation,	 such	as	 the	Ramsey	Scale	or	 the	University	of	Michigan	
Sedation	 Scale	 (UMSS),	 only	 include	 immediate	 response	 to	 com-
mands	or	physical	stimulation,	may	be	less	appropriate	than	a	scale	
such	as	the	Pasero	Opioid	Sedation	Score	(POSS).	These	scales	re-
quire	that	the	rater	stimulate	the	patient	and	subsequently	evaluate	
respiratory	 rate,	 depth,	 and	 pattern.	 Common	 sense	 requires	 res-
piratory	 evaluation	 in	 patients	 receiving	 opioid	 analgesia	 be	 done	
before	stimulating	the	patient	since	measures	after	patient	stimula-
tion	are	inaccurate.	The	POSS	grades	the	“drowsiness”	of	a	patient	
based	 on	 the	 difficulty	 staying	 awake	 or	 being	 aroused	 during	 an	
examination.	It	also	evaluates	the	ability	of	a	patient	to	have	a	con-
versation	with	the	rater	and	determines	whether	somnolence	causes	
the	patient	to	fall	asleep	during	conversation.192,193	This	scale	also	
includes	suggested	measures	to	respond	to	moderate	(reduce	opioid	
dose	and	observe)	to	excessive	sedation	(stop	the	opioid,	administer	
naloxone).	It	is	important	to	note	there	are	no	published	data	demon-
strating	the	POSS	is	effective	in	preventing	opioid‐related	adverse	
outcomes	in	clinical	pediatric	settings.	In	spite	of	this,	the	inclusion	
of	 a	measure	 such	as	 the	POSS	 is	 a	 logical	 tool	 to	assess	 the	opi-
oid‐related	sedation	effect	and	is	preferable	to	scales	developed	for	
procedural	sedation,	which	also	lack	any	evidence	for	effectiveness	
in	this	setting.
Recommendation:	Patients	receiving	opioid	analgesia	periopera-
tively	should	have	regular	assessment	of	their	level	of	sedation	using	
a	validated	sedation	score	that	evaluates	level	of	alertness	or	men-
tation,	rather	than	utilizing	a	procedural	sedation	scale.	This	rating	
should	be	part	of	the	medical	record	along	with	measures	of	pain	and	
physiological	status.
Strength	of	Evidence:	C.
12.4 | Institutional surveillance/safety review for 
opioid‐related adverse events
Surveillance	 for	 opioid‐related	 adverse	 events	 has	 been	 recom-
mended	 including	 regular	 review	 of	 rapid	 response	 team	 and/
or	 code	 team	 calls	 and	 the	 need	 for	 naloxone	 administration.	
Publications	of	 institutional	 review	procedures	of	 this	 nature	pro-
vide	information	regarding	risk	for	adverse	events	in	both	adults	and	
children.174,194,195	 Sophisticated	 filtering	 of	 physiologic	monitoring	
data	has	been	reported	to	detect	prevalence	of	desaturation	events	
in	patients	receiving	opioids.196	Importantly,	concerns	have	recently	
been	 raised	about	 the	 contribution	of	 “alarm	 fatigue”	 to	 failure	 to	
rescue	with	respect	to	opioid	overdose.197
Recommendation:	 Review	 of	 code	 team	 calls	 or	 emergency	 re-
sponse	calls	and	delivery	of	emergent	naloxone	doses	should	be	part	
of	institutional	efforts	to	critically	evaluate	and	reduce	preventable	
opioid‐related	adverse	events.
Strength of evidence:	B.
13  | OPIOID SIDE EFFEC TS IN CHILDREN
Topics	covered	in	this	section:
•	 Prevalence	and	management	of	pruritis,	emesis,	and	ileus.
13.1 | Pruritus
Opioid‐induced	 pruritus	 is	 a	 common	 problem,	 with	 reported	 in-
cidences	 between	 2%	 and	 10%	 for	 intravenous	 morphine.59	 The	
mechanism	is	not	understood,	but	central	mu‐receptor	activity	likely	
has	an	important	influence.	In	the	case	of	morphine,	histamine	and	
mast	cell	mediator	release	may	affect	peripheral	receptors.	Studies	
of	 treatment	 of	 opioid‐induced	 pruritus	 have	 been	 limited,	 par-
ticularly	 for	 intravenously	 administered	opioids.	Most	 notable	 is	 a	
randomized	controlled	trial	of	184	children	greater	than	7	years	old	
treated	with	PCA,	given	50	mcg/kg	of	nalbuphine	for	itch.	The	au-
thors	found	no	benefit	of	nalbuphine.198	Nevertheless,	a	systematic	
review	of	10	adult	 studies	 found	overall	benefit	of	nalbuphine	 for	
treatment	of	opioid‐induced	pruritus.199
Naloxone	 has	 a	 mixed	 track	 record	 in	 pediatric	 perioperative	
care.	West	et	al	found	no	effect	on	itch	in	a	randomized	controlled	
pediatric	 trial	 of	 naloxone/morphine	 admixture	 in	PCA.200	On	 the	
other	 hand,	 a	 randomized	 controlled	 trial	 with	 naloxone	 infusion	
given	to	children	separately	from	the	patient‐controlled	intravenous	
morphine,	in	a	dose	finding	study,	Monitto	and	colleagues201	found	
naloxone	to	be	effective	for	treatment	of	itch	in	over	90%	of	cases	at	
a	dose	of	1	mcg/kg/h,	without	reversing	analgesia	or	increasing	re-
quired	morphine	doses.	A	randomized	controlled	trial	of	46	pediatric	
patients	using	postoperative	PCA	found	less	pruritus	with	low‐dose	
(0.25	mcg/kg/h)	naloxone	infusion	than	placebo	and	that	pain	con-
trol	was	not	adversely	affected.202
Recommendation:	 Naloxone	 infusion	 is	 helpful	 in	 treating	 and	
possibly	preventing	opioid‐induced	pruritus.
Strength of evidence:	A.
Recommendation:	Expert	consensus	supports	 the	use	of	nalbu-
phine	although	there	is	conflicting	evidence	concerning	its	effective-
ness	at	this	time.
Strength of evidence:	C.
13.2 | Emesis
There	are	many	 studies	of	perioperative	nausea	and	vomiting	 in	
children,	but	few	evaluating	the	effect	of	opioid	on	the	incidence	
of	 perioperative	 nausea	 and	 vomiting.	Most	 of	 these	 have	 been	
studies	in	surgical	populations	with	a	high	incidence	of	nausea	and	
vomiting	such	as	tonsillectomy	and	adenoidectomy	or	strabismus	
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surgery.	Perioperative	opioids	are	known	to	 increase	postopera-
tive	nausea	and	vomiting	when	compared	to	nonsteroidal	anti‐in-
flammatory	drugs.203,204	The	magnitude	of	this	effect	varies	with	
the	type	of	surgery	performed,	anesthesia	used,	and	patient	popu-
lation	studied.	Moiniche	et	al	 reported	nausea	and	vomiting	as	a	
secondary	endpoint	 in	a	systematic	 review	of	NSAIDs	compared	
to	opioid	 for	 tonsillectomy	analgesia.	The	use	of	NSAIDs	signifi-
cantly	improved	nausea	and	vomiting	when	compared	to	opioids.	
This	finding	is	consistent	in	several	other	studies	of	perioperative	
opioid	 use	 in	 children.205-208	 Conversely,	 in	 a	 prospective,	 rand-
omized	 controlled	 trial	 of	 children	 given	 a	 propofol‐based	 anes-
thetic	 and	 dexamethasone	 for	 nausea	 and	 vomiting	 prophylaxis,	
Keidan	et	al	compared	ketorolac	to	fentanyl209	and	found	no	ap-
preciable	difference	in	postoperative	nausea	and	vomiting	in	chil-
dren	 (baseline	 rate	was	much	 lower).	 Double‐blind,	 randomized,	
controlled	trials	show	that	the	choice	of	anesthetic	technique,	the	
surgical	procedure,	and	pharmacological	prophylaxis	affect	the	in-
cidence	of	postoperative	nausea	and	vomiting	specifically	related	
to	intraoperative	opioid	use210-215	as	do	lower	morphine	doses.216 
Eberhart	et	al217	evaluated	the	contribution	of	opioids	to	periop-
erative	nausea/vomiting	in	a	meta‐analysis	of	propofol	vs	inhaled	
agents	for	maintenance	of	anesthesia.	This	group	did	not	find	that	
intraoperative	opioids	increased	the	risk	of	postoperative	nausea	
and	vomiting.	Another	systematic	 review	of	13	randomized	con-
trolled	pediatric	trials	of	morphine	compared	to	placebo	or	active	
control	found	that	morphine	had	a	significantly	greater	incidence	
of	nausea	than	the	active	controls,	including	nerve	blocks,	trama-
dol,	buprenorphine,	and	ketorolac.203
Similarly	 in	 some	 instances	 the	 same	studies	as	mentioned	 for	
investigation	of	pruritus,	the	use	of	 low‐dose	continuous	naloxone	
infusion	has	been	studied	for	the	prevention	of	nausea	and	vomit-
ing.	A	 randomized	controlled	 trial	of	pediatric	patients	using	post-
operative	 PCA	 found	 less	 nausea	 with	 0.25	 mcg/kg/h	 naloxone	
infusion	when	compared	to	placebo.	A	dose	finding	study	involving	
59	pediatric	patients	found	that	infusion	rates	greater	than	or	equal	
to	1	mcg/kg/h	 led	 to	 significantly	 less	nausea	 than	 lower	 infusion	
rates.218	As	mentioned	previously,	when	used	 in	 low	doses,	nalox-
one	has	not	been	shown	to	significantly	affect	pain	control	or	opioid	
usage.202,218	Several	other	medications	such	as	transdermal	scopol-
amine,219	 5‐HT3	 receptor	 antagonists	 (ie	 tropisetron,220	 ondanse-
tron,203	ramosetron203),	and	dixyrazine221	have	also	been	shown	to	
decrease	the	incidence	of	nausea	and	vomiting	for	postsurgical	pa-
tients	utilizing	PCA	opioids	for	analgesia.	Each	of	these	agents	has	
a	small	risk	of	causing	other	side	effects.	Agents	with	anticholiner-
gic	and	antihistaminic	actions	contribute	to	postoperative	delirium,	
sedation,	and	bowel	and	bladder	dysfunction.	Nalbuphine	has	been	
found	to	be	ineffective	in	pediatric	patients	for	PCA‐related	nausea	
and	vomiting.222
Recommendation:	Opioid	use	should	be	minimized	where	possi-
ble	to	decrease	the	incidence	of	nausea	and	vomiting	(see	section	on	
Impact	of	Adjunctive	Medications	on	Opioid	Dosing	and	Side	Effects	
for	specific	medication	recommendations).
Strength of evidence:	A.
Recommendation:	Naloxone	infusion	should	be	considered	for	in-
travenous	opioid	therapy	for	the	prevention	or	treatment	of	nausea	
and	vomiting.
Strength of evidence:	A.
Recommendation:	 It	 is	 reasonable	 to	 consider	 common	 anti‐
emetic	medications	for	the	treatment	or	prevention	of	nausea	and	
vomiting	while	on	intravenous	opioid	therapy.	Preference	should	be	
for	nonsedating	medications.
Strength of evidence:	A.
13.3 | Perioperative opioids and ileus
A	common	complication	of	opioids	in	both	the	acute	and	chronic	care	
setting	 is	 slowing	of	bowel	motility	and	specifically	constipation	or	
ileus.	In	the	acute	care	setting,	this	can	result	in	significant	morbidity	
and	delayed	discharge.	Postoperative	opioid‐related	decreased	bowel	
motility	or	ileus	is	well	documented	in	the	adult	population223,224 and 
is	importantly	associated	with	readmission	in	children.200	Treatment	
and	 incidence	 of	 opioid‐induced	 ileus	 has	 only	minimally	 been	 ex-
plored	in	the	literature	in	infants	and	children.225,226	Contrary	to	adult	
studies,	methylnaltrexone	appears	to	be	helpful	in	children.225-228
Recommendation:	Postoperative	opioid‐induced	ileus	may	be	im-
proved	with	methylnaltrexone	in	infants	and	children.
Strength of evidence:	B.
14  | SUMMARY
The	role	of	opioids	in	the	treatment	of	pediatric	perioperative	pain	
is	evolving,	and	professional	as	well	as	public	concern	about	their	
appropriate	application	is	currently	at	a	high	point.	In	spite	of	these	
concerns,	opioids	remain	a	part	of	the	perioperative	pain	treatment	
armamentarium.	These	recommendations	have	been	formulated	as	
a	guide	to	reinforce	current	concepts	of	safe	and	appropriate	use	
of	 these	potent	medications.	We	do	not	present	 them	as	a	com-
prehensive	guide	for	all	patient	encounters,	but	rather	as	a	specific	
set	of	 recommendations	 for	practice	 involving	specific	 situations	
where	opioids	 are	employed.	To	 the	greatest	 extent	possible	we	
have	utilized	published	evidence	to	formulate	these	recommenda-
tions	however	it	is	clear	that	many	of	these	recommendations	lack	
sufficient	evidence	to	make	firm,	evidence‐based	conclusions.	We	
hope	that	researchers	involved	in	pediatric	pain	management	will	
utilize	some	of	the	discussions	and	conclusions	as	a	guide	for	fu-
ture	clinical	trials	and	outcome	analysis.	The	taskforce	involved	in	
these	 recommendations	will	 update	 them	every	2	years	 and	dis-
seminate	the	updated	recommendations	through	the	SPA	Website	
(www.pedsa	nesth	esia.org)	as	well	as	peer	reviewed	publication.
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APPENDIX 
TA B L E  A 1  Database	searches	for	evidence	for	this	document
The	databases/search	engines	utilized	for	this	set	of	recommen-
dations	included	PubMed,	Medline,	Web	of	Science,	EMBASE,	
Google	Scholar,	National	Guideline	Clearinghouse.	Only	English	
language	papers	were	included.	In	many	cases	thousands	of	papers	
were	generated.	The	author	responsible	for	each	section	reviewed	
papers	for	relevance	to	the	specific	topics	that	would	be	covered	
and	graded	the	evidence.	The	search	results	were	then	made	avail-
able	for	review	to	the	entire	group	of	authors:
Age‐related effects section
Opioids AND pediatrics AND (pharmacokinetics OR pharmacodynamics)
((“analgesics,	opioid”[mesh]	OR	opioid[tiab]	OR	opioids[tiab])	
AND	(pediatrics[mesh]	OR	pediatric[tiab]	OR	pediatrics[tiab])	
AND	((pharmacokinetics[mesh]	OR	pharmacokinetics[tiab])	OR	
pharmacodynamics[tiab]))
Opioids AND pediatrics AND respiratory depression
((“analgesics,	opioid”[mesh]	OR	opioid[tiab]	OR	opioids[tiab])	AND	
(pediatrics[mesh]	OR	pediatric[tiab]	OR	pediatrics[tiab])	AND	(“res-
piratory	insufficiency”[mesh]	OR	“respiratory	insufficiency”[tiab]	
OR	“respiratory	depression”[tiab]	OR	“ventilator	depression”[tiab]))
Chest wall rigidity
(((“thoracic	wall”[mesh]	OR	“thoracic	wall”[tiab]	OR	“chest	wall”[tiab])	
AND	(“muscle	rigidity”[mesh]	OR	rigidity[tiab]))	OR	(“chest	wall	
rigidity”[tiab]	OR	“thoracic	wall	rigidity”[tiab]))
Opioids AND metabolism
((“analgesics,	opioid”[mesh]	OR	opioid[tiab]	OR	opioids[tiab])	AND	
(metabolism[mesh]	OR	metabolism[tiab]))
Neonates AND opioids AND pharmacokinetics
((“infant,	newborn”[mesh]	OR	infant[tiab]	OR	infants[tiab]	
OR	newborn[tiab]	OR	newborns[tiab]	OR	neonate[tiab]	
OR	neonates[tiab])	AND	(“analgesics,	opioid”[mesh]	OR	
opioid[tiab]	OR	opioids[tiab])	AND	(pharmacokinetics[mesh]	OR	
pharmacokinetics[tiab]))
Neonates AND opioids AND pharmacodynamics
((“infant,	newborn”[mesh]	OR	infant[tiab]	OR	infants[tiab]	
OR	newborn[tiab]	OR	newborns[tiab]	OR	neonate[tiab]	OR	
neonates[tiab])	AND	(“analgesics,	opioid”[mesh]	OR	opioid[tiab]	OR	
opioids[tiab])	AND	(pharmacodynamics[tiab]))
Neonates AND fentanyl
((“infant,	newborn”[mesh]	OR	infant[tiab]	OR	infants[tiab]	
OR	newborn[tiab]	OR	newborns[tiab]	OR	neonate[tiab]	OR	
neonates[tiab])	AND	(fentanyl[mesh]	OR	fentanyl[tiab]	OR	
phentanyl[tiab]	OR	fentanest[tiab]	OR	sublimaze[tiab]	OR	
duragesic[tiab]	OR	durogesic[tiab]	OR	fentora[tiab]))
Neonates AND morphine
((“infant,	newborn”[mesh]	OR	infant[tiab]	OR	infants[tiab]	
OR	newborn[tiab]	OR	newborns[tiab]	OR	neonate[tiab]	OR	
neonates[tiab])	AND	(morphine[mesh]	OR	morphine[tiab]	OR	
contin[tiab]	OR	oramorph[tiab]	OR	duramorph[tiab]))
Neonates AND sufentanil
((“infant,	newborn”[mesh]	OR	infant[tiab]	OR	infants[tiab]	
OR	newborn[tiab]	OR	newborns[tiab]	OR	neonate[tiab]	OR	
neonates[tiab])	AND	(sufentanil[mesh]	OR	sufentanil[tiab]	
OR	sulfentanyl[tiab]	OR	sulfentanil[tiab]	OR	sufenta[tiab]	OR	
sufentanilratiopharm[tiab]))
(Continues)
Neonates AND remifentanil
((“infant,	newborn”[mesh]	OR	infant[tiab]	OR	infants[tiab]	
OR	newborn[tiab]	OR	newborns[tiab]	OR	neonate[tiab]	OR	
neonates[tiab])	AND	(remifentanil[Supplementary	Concept]	OR	
remifentanil[tiab]	OR	ultiva[tiab]))
PCA section
Analgesia
(analgesia[mesh]	OR	analgesia[tiab]	OR	analgesics[mesh]	OR	
analgesics[tiab]	OR	analgesic[tiab])
Patient‐controlled AND analgesia
((analgesia[mesh]	OR	analgesia[tiab]	OR	analgesics[mesh]	OR	
analgesics[tiab]	OR	analgesic[tiab])	AND	“patient	controlled”[tiab])
Patient‐controlled AND analgesia AND (child OR pediatrics)
(analgesia[mesh]	OR	analgesia[tiab]	OR	analgesics[mesh]	OR	
analgesics[tiab]	OR	analgesic[tiab])	AND	“patient	controlled”[tiab]	
AND	((pediatrics[mesh]	OR	pediatric[tiab]	OR	pediatrics[tiab])	OR	
(child[mesh]	OR	child[tiab]	OR	children[tiab]))
Monitoring section
(“monitoring,	physiologic”[mesh]	OR	“drug	monitoring”[mesh]	OR	
“drug	monitoring”[tiab]	OR	“monitoring”[tiab])
Opioid administration
(“analgesics,	opioid/administration”[mesh]	OR	((“adminis-
tration,	intravenous”[mesh]	OR	“drug	therapy”[mesh]	OR	
administration[tiab])	AND	(“analgesics,	opioid”[mesh]	OR	
opioid[tiab]	OR	opioids[tiab])))
Inpatient
(Inpatients[mesh]	OR	inpatients[tiab]	OR	inpatient[tiab])
Clinical practice guidelines
(“practice	guidelines	as	topic”[mesh]	OR	guideline[publication	type]	
OR	guidelines[tiab]	OR	guideline[tiab])
Patient‐controlled analgesia
((analgesia[mesh]	OR	analgesia[tiab]	OR	analgesics[mesh]	OR	
analgesics[tiab]	OR	analgesic[tiab])	AND	(“patient	controlled”[tiab]	
OR	“patient	controlled	analgesia”[tiab]))
PCA
((analgesia[mesh]	OR	analgesia[tiab]	OR	analgesics[mesh]	OR	
analgesics[tiab]	OR	analgesic[tiab])	AND	(“patient	controlled”[tiab]	
OR	“patient	controlled	analgesia”[tiab]	OR	PCA[tiab]))
Pediatric
(pediatrics[mesh]	OR	pediatric[tiab]	OR	pediatrics[tiab])
Parent
(parents[mesh]	OR	parents[tiab]	OR	parent[tiab])
Nurse
(nurses[mesh]	OR	nursing[mesh]	OR	nurses[tiab]	OR	nurse[tiab])
PCA by proxy
((analgesia[mesh]	OR	analgesia[tiab]	OR	analgesics[mesh]	OR	
analgesics[tiab]	OR	analgesic[tiab])	AND	(“patient	controlled”[tiab]	
OR	“patient	controlled	analgesia”[tiab]	OR	PCA[tiab])	AND	
(proxy[mesh]	OR	proxy[tiab]))
Critical events in inpatient receiving opioid
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((“medical	errors”[mesh]	OR	“medical	errors”[tiab]	OR	“medi-
cal	error”[tiab]	OR	“medical	mistakes”[tiab]	OR	“medical	
mistake”[tiab]	OR	“wrong	procedure	errors”[tiab]	OR	“wrong	
procedure	error”[tiab]	OR	“critical	medical	incidents”[tiab]	OR	
“critical	medical	incident”[tiab]	OR	“critical	incidents”[tiab]	
OR	“critical	incident”[tiab]	OR	“never	events”[tiab]	OR	“never	
event”[tiab]	OR	“critical	events”[tiab]	OR	“critical	event”[tiab])	AND	
(Inpatients[mesh]	OR	inpatients[tiab]	OR	inpatient[tiab])	AND	(“an-
algesics,	opioid”[mesh]	OR	opioid[tiab]	OR	opioids[tiab]))
Critical event alerts networked monitoring
((“medical	errors”[mesh]	OR	“medical	errors”[tiab]	OR	“medi-
cal	error”[tiab]	OR	“medical	mistakes”[tiab]	OR	“medical	
mistake”[tiab]	OR	“wrong	procedure	errors”[tiab]	OR	“wrong	
procedure	error”[tiab]	OR	“critical	medical	incidents”[tiab]	OR	
“critical	medical	incident”[tiab]	OR	“critical	incidents”[tiab]	
OR	“critical	incident”[tiab]	OR	“never	events”[tiab]	OR	“never	
event”[tiab]	OR	“critical	events”[tiab]	OR	“critical	event”[tiab])	
AND	(“monitoring,	physiologic”[mesh]	OR	“drug	monitoring”[mesh]	
OR	“drug	monitoring”[tiab]	OR	“event	monitoring”[tiab]	OR	
“monitoring”[tiab]))
Hospital surveillance for critical events
((“medical	errors”[mesh]	OR	“medical	errors”[tiab]	OR	“medical	
error”[tiab]	OR	“medical	mistakes”[tiab]	OR	“medical	mistake”[tiab]	
OR	“wrong	procedure	errors”[tiab]	OR	“wrong	procedure	
error”[tiab]	OR	“critical	medical	incidents”[tiab]	OR	“critical	
medical	incident”[tiab]	OR	“critical	incidents”[tiab]	OR	“critical	
incident”[tiab]	OR	“never	events”[tiab]	OR	“never	event”[tiab]	OR	
“critical	events”[tiab]	OR	“critical	event”[tiab])	AND	(“monitoring,	
physiologic”[mesh]	OR	monitoring[tiab]	“event	monitoring”[tiab]	
OR	surveillance[tiab]))
Respiratory monitoring technologies
((“monitoring,	physiologic”[mesh]	OR	“drug	monitoring”[mesh]	OR	
“drug	monitoring”[tiab]	OR	“monitoring”[tiab])	AND	(“respiratory	
rate”[mesh]	OR	“respiratory	rate”[tiab])	AND	(technology[mesh]	OR	
technology[tiab]))
Adult and pediatric
((adult[mesh]	OR	adult[tiab])	AND	(pediatrics[mesh]	OR	
pediatric[tiab]	OR	pediatrics[tiab]))
Smart systems
(“smart	systems”[tiab]	OR	“smart	system”[tiab]	OR	(smart[tiab]	AND	
(systems[tiab]	OR	system[tiab])))
Monitoring pain levels section
Opioid
(“analgesics,	opioid”[mesh]	OR	opioid[tiab]	OR	opioids[tiab]))
Pain assessment
(“pain	measurement”[mesh]	OR	“pain	measurement”[tiab]	OR	
“pain	measurements”[tiab]	OR	“pain	assessment”[tiab]	OR	
“pain	assessments”[tiab]	OR	“analgesia	test”[tiab]	OR	“analgesia	
tests”[tiab]	OR	“nociception	test”[tiab]	OR	“nociception	tests”[tiab]	
OR	“pain	questionnaire”[tiab]	OR	“pain	questionnaires”[tiab]	OR	
“pain	scale”[tiab]
OR	“pain	scales”[tiab]	OR	“formalin	test”[tiab]	OR	“formalin	
test”[tiab]	OR	“pain	test”[tiab]	OR	“pain	tests”[tiab])
Children
(child[mesh]	OR	child[tiab]	OR	children[tiab])
Human
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(humans[mesh]	OR	humans[tiab]	OR	human[tiab])
Side effects section
Infant
(infant[mesh]	OR	infant[tiab]	OR	infants[tiab])
Neonate
(“infant,	newborn”[mesh]	OR	infant[tiab]	OR	infants[tiab]	
OR	newborn[tiab]	OR	newborns[tiab]	OR	neonate[tiab]	OR	
neonates[tiab])
Child
(child[mesh]	OR	child[tiab]	OR	children[tiab])
Adolescent/teen
(adolescent[mesh]	OR	adolescent[tiab]	OR	adolescents[tiab]	OR	
teen[tiab]	OR	teens[tiab]	OR	teenager[tiab]	OR	teenagers[tiab]	OR	
youth[tiab]	OR	youths[tiab])
Toddler pediatric AND opioid or opiate
(((toddler[tiab]	OR	toddlers[tiab])	AND	(pediatrics[mesh]	
OR	pediatric[tiab]	OR	pediatrics[tiab]))	AND	((“analgesics,	
opioid”[mesh]	OR	opioid[tiab]	OR	opioids[tiab])	OR	(“opi-
ate	alkaloids”[mesh]	OR	“opiate	alkaloids”tiab]	OR	“opiate	
alkaloid”[tiab]	OR	“alkaloid	opiates”[tiab]	OR	“alkaloid	opiate”[tiab]	
OR	opiates[tiab]	OR	opiate[tiab])))
Pruritis
(pruritis[mesh]	OR	pruritis[tiab]	OR	itching[tiab])
Urinary retention
(“urinary	retention”[mesh]	OR	“urinary	retention”[tiab])
Constipation
(constipation[mesh]	OR	constipation[tiab]	OR	dyschezia[tiab]	OR	
“colonic	intertia”[tiab])
Drug‐related side effects
(“drug‐related	side	effects	and	adverse	reactions”[mesh]	OR	(“drug‐
related	side	effects	and	adverse	reactions”[tiab]	OR	“side	effects	of	
drugs”[tiab]	OR	“drug	side	effects”[tiab]	“drug	side	effect”[tiab]	OR	
“adverse	drug	reactions”[tiab]	OR	“adverse	drug	reaction”[tiab]	OR	
“adverse	drug	events”[tiab]	OR	“adverse	drug	event”[tiab]	OR	“drug	
toxicity”[tiab]	OR	“drug	toxicities”[tiab])
Paralytic ileus
(“intestinal	pseudo‐obstruction”[mesh]	OR	“intestinal	pseudo‐
obstruction”[tiab]	OR	“intestinal	pseudo‐obstructions”[tiab]	OR	
“paralytic	ileus”[tiab]	OR	“visceral	myopathy”[tiab]	OR	“visceral	
myopathies”[tiab])
Ileus
(ileus[mesh]	OR	ileus[tiab])
Perioperative
(“perioperative	period”[mesh]	OR	“perioperative	period”[tiab]	OR	
“perioperative”[tiab])
Methylnaltrexone OR alvimopan
((methylnaltrexone	[Supplementary	Concept]	OR	
methylnaltrexone[tiab]	OR	“quaternary	ammonium	
naltrexone”[tiab]	OR	“naltrexone	methylbromide”[tiab]	
OR	relistor[tiab]	OR	“naltrexonium	methiodide”[tiab])	OR	
(alvimopan[Supplementary	Concept]	OR	alvimopan[tiab]	OR	
entereg[tiab]))
(Continues)
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Opioid treatment of the patient with chronic pain scheduled for 
major surgery section
Chronic pain and chronic opioids
(“narcotic	dependence”	[mesh]	or	“opiate	dependence”[mesh]	or	
“chronic	narcotic”[mesh}	AND	“Anesthesia/	or	anesthesia	surgery”	
[tiab}	OR	“General	Surgery/	Perioperative	Nursing/	or	periopera-
tive”	[tiab]	or	“Perioperative	Care/	or	Perioperative	Period	postop-
erative”	[tiab]	or	“Postoperative	Care”	OR	“Pain,	Postoperative/	or	
Postoperative	Complications”	or	“Postoperative	Period”	[tiab])
Central sensitization
(“fibromyalgia”	OR	“Fibromyalgia”[mesh]	AND	“metha-
done”	[mesh]	OR	“Methadone/	buprenorphine”	[mesh]	OR	
“Buprenorphine	Opiate	Substitution	Treatment”[mesh]	OR	“opioid	
maintenance”[mesh]	or	S”ubstance	Withdrawal	Syndrome”[mesh])
Abbreviation:	PCA, patient‐controlled	analgesia.
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